SPARTON CORP - FORM 10-Q

SPARTON CORP - FORM 10-Q - May 10, 2011

Attached files

Attached files

Stock widget

Investing forum

SPARTON CORP Reports

Also read

file	filename
EX-31.1 - SECTION 302 CEO CERTIFICATION - SPARTON CORP	dex311.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - SPARTON CORP	dex312.htm
EX-32.1 - SECTION 906 CEO AND CFO CERTIFICATION - SPARTON CORP	dex321.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2011

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-1000

Sparton Corporation

(Exact name of registrant as specified in its charter)


Ohio		38-1054690
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

425 N. Martingale Road, Suite 2050, Schaumburg, Illinois		60173-2213
(Address of principal executive offices)		(Zip code)

(847) 762-5800

(Registrant’s telephone number, including zip code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of April 30, 2011, there were 10,236,484 shares of common stock, $1.25 par value per share, outstanding.

TABLE OF CONTENTS


PART I	FINANCIAL INFORMATION	3

ITEM 1.	FINANCIAL STATEMENTS	3
	CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2011 AND JUNE 30, 2010 (UNAUDITED)	3
	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2011 and 2010 (UNAUDITED)	4
	CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED MARCH 31, 2011 and 2010 (UNAUDITED)	5
	CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY FOR THE NINE MONTHS ENDED MARCH 31, 2011 and 2010 (UNAUDITED)	6
	NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	7
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	23
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	40
ITEM 4.	CONTROLS AND PROCEDURES	40

PART II	OTHER INFORMATION	40

ITEM 1.	LEGAL PROCEEDINGS	40
ITEM 1A.	RISK FACTORS	40
ITEM 6.	EXHIBITS	41

SIGNATURES		42

CERTIFICATIONS

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

SPARTON CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Dollars in thousands, except share data)


	March 31, 2011			June 30, 2010 (a)
Assets
Current Assets:
Cash and cash equivalents	$	26,119		$	30,589
Restricted cash		—			3,162
Accounts receivable, net of allowance for doubtful accounts of $118 and $532, respectively		22,073			17,967
Inventories and cost of contracts in progress, net		40,282			26,514
Income taxes receivable		304			296
Deferred income taxes		57			57
Property held for sale		—			3,900
Prepaid expenses and other current assets		1,986			1,449

Total current assets		90,821			83,934
Property, plant and equipment, net		10,831			8,924
Goodwill		20,625			19,141
Other intangible assets, net		5,914			4,803
Other non-current assets		2,869			3,059

Total assets	$	131,060		$	119,861


Liabilities and Shareholders’ Equity
Current Liabilities:
Current portion of long-term debt	$	124		$	121
Accounts payable		17,116			13,045
Accrued salaries and wages		5,042			5,737
Accrued health benefits		985			989
Current portion of pension liability		165			1,139
Restructuring accrual		152			233
Advance billings on customer contracts		19,279			21,595
Other accrued expenses		5,471			3,345

Total current liabilities		48,334			46,204
Deferred income taxes — non-current		1,921			1,579
Pension liability — non-current portion		2,037			1,980
Long-term debt — non-current portion		1,702			1,796
Environmental remediation — non-current portion		3,812			4,033

Total liabilities		57,806			55,592

Commitments and contingencies

Shareholders’ Equity:
Preferred stock, no par value; 200,000 shares authorized, none outstanding		—			—
Common stock, $1.25 par value; 15,000,000 shares authorized, 10,236,484 and 10,200,534 shares outstanding, respectively		12,796			12,751
Capital in excess of par value		20,346			19,864
Retained earnings		43,064			35,026
Accumulated other comprehensive loss		(2,952	)		(3,372	)

Total shareholders’ equity		73,254			64,269

Total liabilities and shareholders’ equity	$	131,060		$	119,861

(a)	Derived from the Company’s audited financial statements as of June 30, 2010.

See Notes to unaudited condensed consolidated financial statements.

SPARTON CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

(Dollars in thousands, except share data)


	For the Three Months Ended						For the Nine Months Ended
	March 31, 2011			March 31, 2010			March 31, 2011			March 31, 2010
Net sales	$	50,352		$	38,637		$	142,450		$	133,964
Cost of goods sold		42,150			33,068			119,675			112,888

Gross profit		8,202			5,569			22,775			21,076

Operating Expense:
Selling and administrative expenses		5,143			4,328			15,666			14,017
Internal research and development expenses		282			—			564			—
Amortization of intangible assets		127			118			347			352
Restructuring/impairment charges		—			238			77			2,121
Gain on acquisition		—			—			(2,400	)		—
Gain on sale of property, plant and equipment, net		(121	)		—			(139	)		—
Other operating expenses		92			507			296			1,120

Total operating expense		5,523			5,191			14,411			17,610

Operating income		2,679			378			8,364			3,466

Other income (expense)
Interest expense		(178	)		(193	)		(529	)		(655	)
Interest income		32			32			118			48
Gain on sale of investment		—			201			—			201
Other, net		105			139			300			255

Total other income (expense), net		(41	)		179			(111	)		(151	)

Income before provision for (benefit from) income taxes		2,638			557			8,253			3,315
Provision for (benefit from) income taxes		115			(132	)		215			(2,027	)

Net income	$	2,523		$	689		$	8,038		$	5,342


Income per share of common stock:
Basic	$	0.25		$	0.07		$	0.79		$	0.54

Diluted	$	0.25		$	0.07		$	0.78		$	0.54


Weighted average shares of common stock outstanding:
Basic		10,223,928			9,978,507			10,211,187			9,964,711


Diluted		10,269,489			9,998,419			10,243,961			9,964,711

See Notes to unaudited condensed consolidated financial statements.

SPARTON CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Dollars in thousands)


	For the Nine Months Ended
	March 31, 2011			March 31, 2010
Cash Flows from Operating Activities:
Net income	$	8,038		$	5,342
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		1,076			1,067
Deferred income tax expense		342			307
Pension expense		427			1,085
Stock-based compensation expense		502			445
Non-cash restructuring/impairment charges		—			252
Gain on sale of property, plant and equipment, net		(139	)		—
Gain on acquisition		(2,400	)		—
Gain on sale of investment		—			(201	)
Other		261			181
Changes in operating assets and liabilities:
Accounts receivable		(2,562	)		19,953
Income taxes receivable		(8	)		(826	)
Inventories and cost of contracts in progress		(1,602	)		9,628
Prepaid expenses and other assets		(602	)		469
Advance billings on customer contracts		(2,316	)		(12,913	)
Accounts payable and accrued expenses		2,428			(19,841	)

Net cash provided by operating activities		3,445			4,948
Cash Flows from Investing Activities:
Purchase of certain contract manufacturing assets of Delphi Medical		(8,419	)		—
Purchase of certain assets of Byers Peak		(4,350	)
Additional goodwill from SMS acquisition		—			(977	)
Change in restricted cash		3,162			(3,151	)
Purchases of property, plant and equipment		(2,274	)		(1,041	)
Proceeds from sale of property, plant and equipment		4,039			450
Proceeds from sale of investment		—			525

Net cash used in investing activities		(7,842	)		(4,194	)
Cash Flows from Financing Activities:
Net short-term bank repayments		—			(15,500	)
Repayment of long-term debt		(98	)		(4,485	)
Payment of debt financing costs		—			(886	)
Proceeds from the exercise of stock options		25			—

Net cash used in financing activities		(73	)		(20,871	)

Net decrease in cash and cash equivalents		(4,470	)		(20,117	)
Cash and cash equivalents at beginning of period		30,589			36,261

Cash and cash equivalents at end of period	$	26,119		$	16,144


Supplemental disclosure of cash flow information:
Cash paid for interest	$	274		$	422
Cash paid (received) for income taxes	$	(81	)	$	5

See Notes to unaudited condensed consolidated financial statements.

SPARTON CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(UNAUDITED)

(Dollars in thousands, except share data)


	Nine Months Ended March 31, 2011
	Common Stock									Accumulated Other Comprehensive Income (Loss)
	Shares		Amount		Capital In Excess of Par Value			Retained Earnings		Accumulated Other Comprehensive Income (Loss)			Total
Balance at June 30, 2010		10,200,534	$	12,751	$	19,864		$	35,026	$	(3,372	)	$	64,269
Issuance of stock		30,950		39		(39	)		—		—			—
Exercise of stock options		5,000		6		19			—		—			25
Stock-based compensation expense		—		—		502			—		—			502
Comprehensive income, net of tax:
Net income		—		—		—			8,038		—			8,038
Change in unrecognized pension costs		—		—		—			—		420			420

Comprehensive income														8,458

Balance at March 31, 2011		10,236,484	$	12,796	$	20,346		$	43,064	$	(2,952	)	$	73,254


	Nine Months Ended March 31, 2010
	Common Stock									Accumulated Other Comprehensive Income (Loss)
	Shares		Amount		Capital In Excess of Par Value			Retained Earnings		Accumulated Other Comprehensive Income (Loss)			Total
Balance at June 30, 2009		9,951,507	$	12,439	$	19,671		$	27,586	$	(4,801	)	$	54,895
Issuance of stock		27,000		34		(34	)		—		—			—
Stock-based compensation expense		—		—		445			—		—			445
Comprehensive income, net of tax:
Net income		—		—		—			5,342		—			5,342
Change in unrecognized pension costs		—		—		—			—		956			956

Comprehensive income		—		—		—			—		—			6,298

Balance at March 31, 2010		9,978,507	$	12,473	$	20,082		$	32,928	$	(3,845	)	$	61,638

See Notes to unaudited condensed consolidated financial statements.

SPARTON CORPORATION AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(1) Business and Basis of Presentation

Sparton Corporation and subsidiaries (the “Company” or “Sparton”) has been in continuous existence since 1900. It was last reorganized in 1919 as an Ohio corporation. The Company is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, and field service. The three primary markets the Company serves are the Medical Device (“Medical”), Defense & Security Systems (“DSS”), and Electronic Manufacturing Services (“EMS”) industries. The Company reports its operating results under these three reportable business segments. Financial information by segment is presented in Note 16. All of the Company’s facilities are registered to ISO standards, including 9001 or 13485, with most having additional certifications. The Company’s products and services include products for Original Equipment Manufacturers (“OEM”) and Emerging Technology (“ET”) customers that are microprocessor-based systems that include transducers, printed circuit boards and assemblies, sensors, and electromechanical components, as well as development and design engineering services relating to these product sales. Sparton also develops and manufactures sonobuoys, an anti-submarine warfare (“ASW”) device, used by the United States Navy and other free-world countries. Many of the physical and technical attributes in the production of sonobuoys are similar to those required in the production of the Company’s other electrical and electromechanical products and assemblies.

The unaudited condensed financial statements and related footnotes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The financial information presented herein should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2010, which includes information and disclosures not presented herein. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain reclassifications of prior period amounts have been made to conform to the current year presentation. Subsequent events have been evaluated through the date these financial statements were issued. In the opinion of management, the unaudited condensed consolidated financial statements contain all of the adjustments, consisting of normal recurring adjustments, necessary to present fairly, in summarized form, the consolidated financial position, results of operations and cash flows of the Company. The results of operations for the three and nine months ended March 31, 2011 are not indicative of the results that may be expected for the full fiscal year 2011.

(2) Acquisitions

Delphi Medical’s Contract Manufacturing Business — On August 6, 2010, the Company completed the acquisition of certain assets related to the contract manufacturing business of Delphi Medical Systems, LLC (“Delphi Medical” or “Delphi”). The purchase price was approximately $8.6 million, including additional consideration paid during the three months ended December 31, 2010 related to determination of the final inventory value. Total cash consideration paid of approximately $8.4 million, including a $2.0 million escrowed holdback, was net of approximately $0.2 million for the assumption of retained employee accruals and was financed entirely through the use of Company cash. The purchase agreement provides for the recovery from Delphi Medical of an amount up to $2.0 million, deposited in escrow at closing, for certain excess and obsolete inventory remaining on-hand at the end of the 18 month period from closing. The escrowed funds are additionally available for payment of potential seller indemnification obligations in relation to the agreement.

The acquired business, which is reported in the Company’s Medical segment, provides a new and diversified customer base and provides Sparton with a geographic presence in the western United States. Delphi Medical primarily manufactures OEM medical devices including blood separation equipment, spinal surgery products and 3-D eye mapping devices. It also provides engineering and manufacturing support to a market-leading environmental sensor company whose markets include meteorology, weather critical operations and controlled environment applications.

The following table represents the preliminary allocation of the total consideration to assets acquired and liabilities assumed from Delphi Medical based on Sparton’s preliminary estimate of their respective fair values (in thousands):


Total purchase consideration:	$	8,419

Assets acquired and liabilities assumed:
Inventory		10,656
Equipment		360
Employee accruals assumed		(197	)

Total assets acquired and liabilities assumed		10,819


Gain on acquisition	$	2,400

Sparton has determined that the fair value of the assets acquired and liabilities assumed related to this acquisition exceed the total purchase consideration and as a result the Company has recorded a gain on acquisition of $2.4 million in the three months ended September 30, 2010. Sparton believes it was able to purchase this contract manufacturing business from Delphi Medical significantly below its fair value due to Delphi’s desire to liquidate this asset in a timely manner and focus on its core business.

Included in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended March 31, 2011 are net sales of approximately $10.5 million and $27.8 million, respectively, and income before provision for income taxes of approximately $1.1 million and $4.7 million, respectively, resulting from the acquisition of Delphi Medical since August 6, 2010.

The Company incurred legal, professional and other costs related to this acquisition aggregating approximately $0.2 million. These costs were recognized as selling and administrative expenses of approximately $0.1 million and $0.1 million in the three months ended September 30, 2010 and June 30, 2010, respectively.

On August 6, 2010 and concurrent with the acquisition of Delphi Medical, the Company entered into leases for two facilities housing the operations of this contract manufacturing business. During the six months ended December 31, 2010, the Company initiated and completed the consolidation of the operations into one facility, and terminated the lease for the building which the Company exited.

Byers Peak — On March 4, 2011, the Company completed the acquisition of certain assets and assumption of certain liabilities of Byers Peak, Incorporated (“Byers Peak”) in an approximate $4.4 million all-cash transaction, subject to certain post-closing adjustments. The transaction was financed through the use of Company cash and included an approximate $0.4 million holdback which is available to fund potential seller indemnification obligations in relation to the agreement.

The acquired business, which is reported in the Company’s Medical segment, provides further expansion into the therapeutic device market, diversifies Sparton’s customer base, and further expands the Company’s geographic reach into the western United States. Additionally, the acquisition increases Sparton’s offerings with the inclusion of field service and refurbishment capabilities. Byers Peak primarily manufactures medical devices for OEM and emerging technology companies in the Therapeutic device market, including devices for surgical navigation, RF energy generation, non-invasive pain relief, arterial disease, and kidney dialysis. It also has a field service and installation group that primarily provides water filtration and disinfection systems for the medical industry as well as device refurbishment programs. Additionally, Byers Peak provides electromechanical device manufacturing support for a limited number of customers outside of the medical industry.

The following table represents the preliminary allocation of the total consideration to assets acquired and liabilities assumed from Byers Peak based on Sparton’s preliminary estimate of their respective fair values (in thousands):


Total purchase consideration:
Cash	$	4,350
Estimated receivable for post-closing adjustment		(210	)

Total purchase consideration	$	4,140

Assets acquired and liabilities assumed:
Accounts receivable, net	$	1,334
Inventory		1,509
Intangible assets – customer relationships		1,300
Intangible assets – non-compete agreements		158
Goodwill		1,484
Accounts payable		(629	)
Customer deposits		(973	)
Other current liabilities		(43	)

Total assets acquired and liabilities assumed	$	4,140

Total purchase consideration was allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. The Byers Peak acquisition resulted in approximately $1.5 million of goodwill, which is expected to be deductible for tax purposes and which was assigned entirely to the Company’s Medical segment. The Company believes goodwill primarily relates to the complimentary strategic fit, resulting synergies and the acquired workforce that this business brings to existing operations. The acquired identifiable intangible assets, aggregating approximately $1.5 million, include customer relationships of $1.3 million and non-compete agreements of approximately $0.2 million. The fair values of acquired identifiable intangible assets were determined to be Level 3 under the fair value hierarchy and were estimated based on future cash flows and customer attrition rates, discounted using an estimated weighted average cost of capital. The customer relationships and non-compete agreements will be amortized on a straight-line basis over ten years and two years, respectively. The straight-line method is being used to amortize the identified intangible assets because the Company does not believe an accelerated pattern of consumption of these assets can be reliably determined, and expected undiscounted cash flows are reasonably consistent with a more ratable decline in value over time.

Included in the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended March 31, 2011 are net sales of approximately $0.3 million and $0.3 million, respectively, and loss before provision for income taxes of approximately $0.1 million and $0.1 million, respectively, resulting from the acquisition of Byers Peak since March 4, 2011.

The Company incurred legal, professional and other costs related to this acquisition aggregating approximately $0.1 million. These costs were recognized as selling and administrative expenses in the three months ended March 31, 2011.

On March 4, 2011 and concurrent with the acquisition of Byers Peak, the Company entered into a six month sublease for the facility housing the operations of this contract manufacturing business. The Company may, at its option, extend the term of this sublease for an additional eighteen month period. In conjunction with the Byers Peak acquisition, the Company intends to consolidate the Byers Peak operations into the Company’s Frederick, Colorado facility. These restructuring activities are expected to commence during the Company’s fiscal 2011 fourth quarter.

Pro Forma Results — The following table summarizes, on a pro forma basis, the combined results of operations of the Company and the acquired contract manufacturing businesses of Delphi Medical and Byers Peak as though the acquisitions had occurred as of July 1, 2009. The pro forma amounts presented are not necessarily indicative of either the actual consolidated results had the acquisition occurred as of July 1, 2009 or of future consolidated operating results (in thousands, except per share amounts):


	For the Three Months Ended				For the Nine Months Ended
	March 31, 2011		March 31, 2010		March 31, 2011		March 31, 2010
Net sales	$	52,154	$	48,064	$	152,514	$	163,650
Income before provision for (benefit from) income taxes	$	2,578	$	314	$	8,073	$	2,517
Net income	$	2,463	$	446	$	7,858	$	4,544
Net income per share – basic	$	0.24	$	0.04	$	0.77	$	0.46
Net income per share – diluted	$	0.24	$	0.04	$	0.77	$	0.46

(3) Inventories and Cost of Contracts in Progress

The following are the approximate major classifications of inventory, net of advance billings, at March 31, 2011 and June 30, 2010 (in thousands):


	March 31, 2011			June 30, 2010
Raw materials	$	39,195		$	23,524
Work in process		8,065			3,611
Finished goods		3,794			6,790

Total inventory and cost of contracts in progress, gross		51,054			33,925
Inventory to which the U.S. government has title due to advance billings		(10,772	)		(7,411	)

Total inventory and cost of contracts in progress, net	$	40,282		$	26,514

The Company recorded inventory write-downs totaling approximately $0.0 million and $0.3 million for the three months ended March 31, 2011 and 2010, respectively, and $0.1 million and $1.3 million for the nine months ended March 31, 2011 and 2010, respectively. These charges are included in cost of goods sold for the periods presented.

(4) Property, Plant and Equipment, Net

Property, plant and equipment, net consists of the following at March 31, 2011 and June 30, 2010 (in thousands):


	March 31, 2011			June 30, 2010
Land and land improvements	$	1,235		$	1,235
Buildings and building improvements		15,318			14,514
Machinery and equipment		14,037			12,342
Construction in progress		710			574

Total property, plant and equipment		31,300			28,665
Less accumulated depreciation		(20,469	)		(19,741	)

Total property, plant and equipment, net	$	10,831		$	8,924

At June 30, 2010, the Company had for sale its Bluewater Road property in Albuquerque, New Mexico and classified this property as Property held for sale. During February 2011, the Company sold its Bluewater Road property for approximately $4.2 million, resulting in a gain on sale of property, after commissions and closing costs, of approximately $0.1 million.

(5) Goodwill and Other Intangible Assets

Goodwill at March 31, 2011 represents the excess of purchase price over the fair value of the net assets acquired in conjunction with the Company’s purchases of Astro Instrumentation, LLC (“Astro”) in May 2006 and Byers Peak in March 2011. Goodwill related to both of these acquisitions is reflected within the Company’s Medical operating segment. Changes in the carrying value of goodwill for the nine months ended March 31, 2011 and year ended June 30, 2010 are as follows (in thousands):


	For the Nine Months Ended March 31, 2011		For the Year Ended June 30, 2010
Goodwill, beginning of period	$	19,141	$	17,694
Additions		1,484		1,447

Goodwill, end of period	$	20,625	$	19,141

The addition to goodwill during the nine months ended March 31, 2011 represents goodwill created resulting from the acquisition of Byers Peak. The addition to goodwill during the year ended June 30, 2010 represents additional consideration earned in relation to the Astro acquisition.

Intangible assets represent the values assigned to customer relationships acquired in conjunction with the Company’s purchases of Astro and Byers Peak. The amortization periods, gross carrying amounts, accumulated amortization and net carrying values of intangible assets at March 31, 2011 and June 30, 2010 are as follows (in thousands):


	March 31, 2011
	Amortization Period in Months		Gross Carrying Amount		Accumulated Amortization			Net Carrying Value
Amortized intangible assets:
Non-compete agreements		24	$	158	$	(6	)	$	152
Customer relationships		120-180		7,900		(2,138	)		5,762

			$	8,058	$	(2,144	)	$	5,914


	June 30, 2010
	Amortization Period in Months		Gross Carrying Amount		Accumulated Amortization			Net Carrying Value
Amortized intangible assets:
Customer relationships		180	$	6,600	$	(1,797	)	$	4,803

Sparton did not incur any significant costs to renew or alter the term of its intangible assets during the nine months ended March 31, 2011. Amortization expense for each of the three months ended March 31, 2011 and 2010 was approximately $0.1 million. Amortization expense for each of the nine months ended March 31, 2011 and 2010 was approximately $0.3 million. Aggregate amortization expense relative to existing intangible assets for the periods shown is currently estimated to be as follows (in thousands):


Fiscal Year Ended June 30,
2011	$	510
2012		649
2013		622
2014		570
2015		570
Thereafter		3,340

Total	$	6,261

(6) Other non-current assets

Other non-current assets consist of the following at March 31, 2011 and June 30, 2010 (in thousands):


	March 31, 2011		June 30, 2010
Deferred financing fees, net	$	452	$	706
Cost method investment in Cybernet Systems Corporation		1,623		1,623
Coors Road long-term lease receivable		493		468
Other		301		262

Total other non-current assets	$	2,869	$	3,059

Costs incurred in connection with the Company’s revolving line-of-credit of approximately $1.0 million were deferred and are amortized to interest expense over the three year term of the facility.

The Company holds an approximate 12% interest in Cybernet Systems Corporation (“Cybernet”), a developer of hardware, software, next-generation network computing, and robotics products. Beginning in February 2010, the Company accounts for its investment in Cybernet under the cost method. Previously, this investment was accounted for under the equity method.

The Company is due three equal annual payments, beginning May 1, 2011 and aggregating approximately $0.8 million, in relation to the long-term lease of its Coors Road property in Albuquerque, New Mexico. The $0.8 million of future payments due have been discounted for the imputation of interest, resulting in a discounted receivable of approximately $0.8 million. Approximately $0.3 million of this discounted receivable is due within the next 12 months and therefore is included in prepaid expenses and other current assets on the balance sheets at March 31, 2011 and June 30, 2010.

(7) Debt

Short-term debt maturities and revolving line of credit — Short-term debt at March 31, 2011 and June 30, 2010 reflects the current portion of the Company’s industrial revenue bonds of approximately $0.1 million.

The Company has $20 million of maximum borrowing availability, subject to certain collateral restrictions, under a revolving line-of-credit facility (the “Facility”) provided in August 2009 by National City Business Credit, Inc. (now PNC Bank, National Association) to support working capital needs and other general corporate purposes. The line-of-credit facility is secured by substantially all of the assets of the Company. Outstanding borrowings bear interest at a variable rate defined as the Bank’s minimum base rate plus a specified margin, each component of which is determined separately for domestic and Eurodollar rate loans. The Facility was amended in March 2011 to reduce the interest rates on domestic and Eurodollar rate based loans, which at March 31, 2011 would have ranged from 3.30% to 5.25% per annum. Prior to the Facility amendment, the Company was subject to higher rates, with a minimum rate of 7% per annum. As a condition of the Facility, the Company is subject to compliance with certain customary covenants, which the Company met at March 31, 2011. The Company had no borrowings drawn against the Facility during the periods ended March 31, 2011 and June 30, 2010, however it did have certain letters of credit outstanding totaling $0.5 million. The maturity date for the line-of-credit is August 14, 2012. The Company’s prior line of credit was retired on August 14, 2009.

Long-term debt — Long-term debt consists of the following at March 31, 2011 and June 30, 2010 (in thousands):


	March 31, 2011			June 30, 2010
Industrial revenue bonds, face value	$	1,932		$	2,029
Less unamortized purchase discount		(106	)		(112	)

Total long-term debt		1,826			1,917
Less: current portion		(124	)		(121	)

Long-term debt, net of current portion	$	1,702		$	1,796

Industrial Revenue Bonds

In connection with its acquisition of Astro in May 2006, the Company assumed repayment of principal and interest on bonds originally issued on behalf of Astro by the State of Ohio. These bonds are Ohio State Economic Development Revenue Bonds, Series 2002-4. Astro originally entered into the loan agreement with the State of Ohio for the issuance of these bonds to finance the construction of Astro’s current operating facility. The principal amount, including premium, was issued in 2002 and totaled approximately $2.9 million. These bonds have interest rates which vary, dependent on the maturity date of the bonds ranging from 5.00% to 5.45%. Due to an increase in interest rates since the original issuance of the bonds, a discount amounting to approximately $0.2 million on the date of assumption by Sparton was recorded.

The bonds carry certain sinking fund requirements generally obligating the Company to make monthly deposits of one twelfth of the annual obligation plus accrued interest. The purchase discount is being amortized ratably over the remaining term of the bonds. Amortization expense for each of the three months ended March 31, 2011 and 2010 was approximately $2,000. Amortization expense for each of the nine months ended March 31, 2011 and 2010 was approximately $7,000. The Company also has an irrevocable letter of credit in the amount of approximately $0.3 million, which is renewable annually, to secure repayment of a portion of the bonds.

Notes Payable — Former Owners

Two notes payable with initial principal of $3.75 million each, totaling $7.5 million, were payable to the sellers of Astro, which is now operated under the Medical segment. These notes were repaid over four years, in aggregate semi-annual payments of principal and interest in the combined amount of approximately $1.1 million on June 1 and December 1 of each year. Payments commenced on December 1, 2006. These notes each bore interest at 5.5% per annum. The notes were proportionately secured by the stock of Astro. On June 1, 2010, the Company made the final payments in satisfaction of these notes.

Bank Term Loan

The bank term loan, provided by National City Bank with an original principal of $10.0 million, was being repaid over five years, with quarterly principal payments of $0.5 million which commenced September 1, 2006. This loan bore interest at the variable rate of LIBOR plus 500 basis points, with interest calculated and paid quarterly along with the principal payment. The debt was secured by substantially all assets of the Company. On August 14, 2009, the Company paid off this term loan with a cash payment in connection with the Facility.

(8) Fair Value Measurements

As of March 31, 2011, the Company has no assets or liabilities which it measures and carries on its balance sheet at fair value on a recurring basis. The Company’s long-term debt instruments, consisting of industrial revenue bonds at March 31, 2011, are carried at historical cost. As of March 31, 2011 and June 30, 2010, the fair value of the industrial revenue bonds was approximately $2.2 million and $2.3 million, respectively compared to carrying values of approximately $1.8 million and $1.9 million, respectively. These fair values were derived from discounted cash flow analyses based on the terms of the contracts and observable market data, including adjustment for non-performance risk. The fair value of accounts receivable and accounts payable approximated their carrying values at both March 31, 2011 and June 30, 2010. In relation to the acquisitions of Delphi Medical and Byers Peak, the Company estimated the fair value of the assets acquired and liabilities assumed at acquisition date. See Note 2 for a further discussion of these estimated fair values.

(9) Income Taxes

The Company’s effective income tax rate for the interim periods presented is based on management’s estimate of the Company’s effective tax rate for the applicable year and differs from the federal statutory income tax rate primarily due to applicable permanent differences, federal alternative minimum taxes, foreign income taxes, state income taxes and changes in the valuation allowance for deferred income taxes. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible.

For both of the three and nine months ended March 31, 2011 and 2010, provisions for income taxes of approximately $0.1 million and $0.3 million, respectively, were recognized relating to the increase in the deferred tax liability associated with the amortization of goodwill for tax purposes. There was no other federal income tax expense recorded for any of the three and nine months ended March 31, 2011 or 2010, as income generated in these periods was offset by the utilization of previously recorded net operating loss carryforwards and the reversal of the related valuation allowance. The Company additionally recorded a benefit of approximately $0.1 million during the nine months ended March 31, 2011 relating to income tax carryback refunds from the Canadian government.

As a result of tax legislation enacted in November 2009, the Company elected during the nine months ended March 31, 2010 to carry back a portion of its fiscal 2008 accumulated net operating loss to fiscal 2003, with this carryback generating a federal income tax refund of $1.7 million. In addition, the Internal Revenue Service issued an industry directive providing guidance for extending the carryback period to ten years for losses related to environmental remediation. The Company elected during the nine months ended March 31, 2010 to carryback its remediation losses from fiscal years 2006 through 2009, generating a federal income tax refund of $0.6 million. As of March 31, 2011 and June 30, 2010, the Company has received $2.0 million of the $2.3 million in refund claims. In conjunction with these carryback tax filings, the Company released $0.2 million and $2.3 million of its deferred tax asset valuation allowance during the three and nine months ended March 31, 2010, respectively.

At June 30, 2010, approximately $15.7 million of U.S. income tax net operating loss carryovers were available to offset the Company’s future Federal taxable income, of which $4.7 million, $5.1 million and $5.9 million expire in 2029, 2028 and 2027, respectively. For state income tax purposes, the Company also had approximately $11.5 million of net operating loss carryovers at June 30, 2010, of which $0.6 million expire in 2011; $1.5 million expire in 2012; $0.9 million expire in 2013; $0.5 million expire in 2014; $3.3 million expire in 2027; $3.1 million expire in 2028; and $1.6 million expire in 2029. While management believes that realization of the deferred tax assets related to these net operating loss carryovers and other net temporary differences is possible, a total valuation allowance of $10.9 million has been established as of June 30, 2010, against the $11.7 million of deferred tax assets available for U.S. income tax purposes.

(10) Defined Benefit Pension Plan

Approximately 600 employees and retirees of the Company are covered by a defined benefit pension plan. Effective April 1, 2009, participation and the accrual of benefits in this pension plan were frozen, at which time all participants became fully vested. The components of net periodic pension expense are as follows for the three and nine months ended March 31, 2011 and 2010 (in thousands):


	For the Three Months Ended						For the Nine Months Ended
	March 31,2011			March 31, 2010			March 31, 2011			March 31, 2010
Service cost	$	—		$	—		$	—		$	—
Interest cost		111			143			335			431
Expected return on plan assets		(109	)		(100	)		(328	)		(302	)
Amortization of prior service cost		—			—			—			—
Amortization of unrecognized net actuarial loss		59			94			176			281

Net periodic benefit cost		61			137			183			410
Pro rata recognition of lump-sum settlements		81			225			244			675

Total periodic pension expense	$	142		$	362		$	427		$	1,085

Lump-sum settlement charges of approximately $0.1 million and $0.2 million were recognized during the three and nine months ended March 31, 2011, respectively, in anticipation of lump-sum benefit distributions exceeding plan service and interest costs for the 2011 fiscal year. Lump-sum settlement charges of approximately $0.2 million and $0.7 million were recognized during the three and nine months ended March 31, 2010. The Company’s policy is to fund the plan based upon tax regulations and required legal funding requirements, as well as discretionary funding to ensure an adjusted funding target attainment percentage of at least 80%. During the three and nine months ended March 31, 2011, approximately $0.1 million and $0.9 million, respectively, was contributed to the pension plan. During the three and nine months ended March 31, 2010, approximately $0.1 million and $1.9 million, respectively, was contributed to the pension plan. For further information on future funding projections and other pension disclosures see Part II, Item 8, Note 8 “Employee Retirement Benefit Plans” of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2010.

(11) Commitments and Contingencies

Environmental Remediation — Sparton has been involved with ongoing environmental remediation since the early 1980’s related to one of its former manufacturing facilities, located in Albuquerque, New Mexico (“Coors Road”). Although the Company entered into a long-term lease of the Coors Road property that was treated as a sale of property during the fourth quarter of fiscal 2010, it remains responsible for the remediation obligations related to its past operation of this facility. At March 31, 2011, Sparton had accrued approximately $4.3 million as its estimate of the remaining minimum future undiscounted financial liability with respect to this matter, of which approximately $0.5 million is classified as a current liability and included on the balance sheet in other accrued expenses. The Company’s minimum cost estimate is based upon existing technology and excludes certain legal costs, which are expensed as incurred. The Company’s estimate includes equipment and operating and maintenance costs for onsite and offsite pump and treat containment systems, as well as continued onsite and offsite monitoring. It also includes periodic reporting requirements.

On October 15, 2009, approximately $3.1 million of cash was utilized to establish a trust, the Sparton Corporation Financial Assurance Trust, for remediation activity. The funds were held in Sparton’s name and were invested with Sparton receiving the benefit of the investment return. As of June 30, 2010, approximately $3.2 million was held in this trust. These funds were available for use against the expected remediation liability. The trust was established to meet the United States Environmental Protection Agency’s (“EPA”) financial assurance requirements for the fiscal year ended June 30, 2010, with trust funds to be drawn upon only should Sparton not continue to meet its financial remediation requirements. The trust was to remain in place until the Company could again satisfy the EPA financial assurance requirements through compliance with financial ratios, as was previously attained on an annual basis until fiscal year 2009. Based on the Company’s financial results for fiscal year 2010, the Company was again in compliance with the financial ratios and dissolved the trust during October 2010.

In fiscal 2003, Sparton reached an agreement with the United States Department of Energy (“DOE”) and others to recover certain remediation costs. Under the settlement terms, Sparton received cash and obtained some degree of risk protection as the DOE agreed to reimburse Sparton for 37.5% of certain future environmental expenses in excess of $8.4 million incurred from the date of settlement, if any, of which approximately $3.4 million has been expended as of March 31, 2011 toward the $8.4 million threshold. Uncertainties associated with environmental remediation contingencies are pervasive and often result in wide ranges of reasonably possible outcomes. Estimates developed in the early stages of remediation can vary significantly. Normally a finite estimate of cost does not become fixed and determinable at a specific point in time. Rather, the costs associated with environmental remediation become estimable over a continuum of events and activities that help to frame and define a liability. Factors which cause uncertainties for the Company include, but are not limited to, the effectiveness of the current work plans in achieving targeted results and proposals of regulatory agencies for desired methods and outcomes. It is possible that cash flows and results of operations could be materially affected by the impact of changes associated with the ultimate resolution of this contingency. At March 31, 2011, the Company estimates that there is a reasonable possibility that future environmental remediation costs associated with the Company’s past operations at the Coors Road property, in excess of amounts already recorded and net of DOE reimbursement, could be up to $1.1 million before income taxes over the next approximately twenty years.

The Company and its subsidiaries are also involved in certain existing compliance issues with the EPA and various state agencies, including being named as a potentially responsible party at several sites. Potentially responsible parties (“PRP”s) can be held jointly and severally liable for the clean-up costs at any specific site. The Company’s past experience, however, has indicated that when it has contributed relatively small amounts of materials or waste to a specific site relative to other PRPs, its ultimate share of any clean-up costs has been minor. Based upon available information, the Company believes it has contributed only small amounts to those sites in which it is currently viewed as a PRP.

Customer Relationships — The Company had an action before the U.S. Court of Federal Claims to recover damages arising out of an alleged infringement by the U.S. Navy of certain patents held by Sparton and used in the production of sonobuoys. Pursuant to an agreement between the Company and counsel conducting the litigation, a significant portion of the claim will be retained by the Company’s counsel in contingent fees if the litigation is successfully concluded. A trial of the matter was conducted by the court in April 2008, with a decision against Sparton filed in August 2009 and published in September 2009. In October 2009, an appeal of this unfavorable decision was filed with the Federal Circuit Court of Appeals. Based on this decision, management believes that the Company’s ability to obtain any recovery with respect to the claim is remote.

Litigation — On August 9, 2009, Sparton and certain subsidiaries were named as defendants in a wrongful death suit, alleging that a defective transmission shifter assembly in a 1996 Chrysler automobile caused a July 2007 death. The suit also named Chrysler LLC, Dura Automotive Systems, Inc., and Chandler Motors Company as defendants. The suit was filed in Pontotoc County Circuit Court in Mississippi. Sparton has not manufactured automotive shifter assemblies for Chrysler since December 1996, when it sold its KPI Group subsidiary to Dura Automotive Systems, Inc. The plaintiff seeks damages from the defendants for economic loss, pain and suffering, and loss of companionship, as well as punitive damages. Sparton has denied liability, has notified its insurance carriers regarding this claim, and is vigorously defending this matter. At this time, it is not possible to determine or predict the outcome of this suit, and as a result, no amounts have been accrued in the financial statements as of March 31, 2011. While no assurances can be given, the Company does not believe that this litigation, if adversely determined, would have a material adverse affect on the Company’s financial position or results of operations.

Other — In addition to the foregoing, from time to time, the Company is involved in various legal proceedings relating to claims arising in the ordinary course of business. The Company is not currently a party to any other such legal proceedings, the adverse outcome to which, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition or results of operations.

(12) Stock-Based Compensation

The Company has two long-term incentive plans. The Sparton Corporation Stock Incentive Plan, as amended and restated (the “2001 Plan”) was approved by the Company’s shareholders on October 24, 2001. The Sparton Corporation 2010 Long-Term Incentive Plan (the “2010 Plan”) was approved by the Company’s shareholders on October 28, 2009.

2001 Plan. Under the 2001 Plan, the Company may grant to employees and non-employee directors incentive or non-qualified stock options, stock appreciation rights, restricted stock and other stock-based awards. All of the stock options issued to date under the 2001 Plan have either three, five or ten-year lives with either immediate vesting or vesting on an annual basis over four years beginning one year after grant date. Restricted stock awards granted to date to employees under the 2001 Plan vest annually over periods ranging from approximately 2.5 to 3.5 years. Unrestricted stock awards granted to date under the 2001 Plan represent annual stock grants to directors as a component of their overall compensation. The 2001 Plan’s termination date with respect to the granting of new awards is October 24, 2011. The total number of shares that may be granted under the 2001 Plan is 970,161 shares of the Company’s common stock, of which amount, 36,495 shares remain available for awards as of March 31, 2011.

2010 Plan. Under the 2010 Plan, the Company may grant to employees, officers and directors of the Company or its subsidiaries incentive and non-qualified stock options, stock appreciation rights, restricted stock or restricted stock units, performance awards and other stock-based awards, including grants of shares. Restricted stock awards granted to date to employees under the 2010 Plan vest annually over four years, subject to achievement of certain financial performance metrics in addition to the service requirements. The 2010 Plan has a term of ten years. The total number of shares that may be awarded under the 2010 Plan is 1,000,000 shares of common stock, of which amount, 777,973 shares remain available for awards as of March 31, 2011.

The Company did not grant any stock options during the nine months ended March 31, 2011. During the nine months ended March 31, 2010, the Company awarded an aggregate of 111,250 stock options to certain members of management at an exercise price of $5.00. The stock options were immediately exercisable. The closing price of the Company’s stock on the date of grant was $4.59. The fair value of each grant is estimated at the grant date using the Black-Scholes option pricing method. The table below outlines the assumptions used for the options granted during the nine months ended March 31, 2010:


	Weighted Average
Risk free interest rate		1.25	%
Volatility		78.10	%
Dividend yield		0.00	%
Expected life in years		3.00
Fair value price	$	2.25

The risk-free interest rate was determined using the then implied yield currently available for zero-coupon U.S. government issues with a remaining term equal to the expected life of the stock options. The expected volatility assumption used in the Black-Scholes option pricing models was based on the historical volatility of the Company’s common stock. The Company does not currently intend to pay cash dividends and thus has assumed a 0% dividend yield. The Company estimates the expected life for stock options based on expected future exercise patterns.

The following table shows stock-based compensation expense by type of share-based award for the three and nine months ended March 31, 2011 and 2010 included in the condensed consolidated statements of operations (in thousands):


	For the Three Months Ended				For the Nine Months Ended
	March 31, 2011		March 31, 2010		March 31, 2011		March 31, 2010
Fair value expense of stock option awards	$	—	$	7	$	—	$	270
Restricted stock		130		54		502		175

Total stock-based compensation	$	130	$	61	$	502	$	445

The following table shows the total remaining unrecognized compensation cost related to restricted stock grants and the fair value expense of stock option awards, as well as the weighted average remaining required service period over which such costs will be recognized as of March 31, 2011:


	Total Remaining Unrecognized Compensation Cost		Weighted Average Remaining Required Service Period
	(in thousands)		(in years)
Fair value expense of stock option awards	$	—		—
Restricted stock		784		2.16

	$	784		2.16

The following is a summary of options outstanding and exercisable at March 31, 2011:


	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Intrinsic Value
						(in years)		(in thousands)
Outstanding at June 30, 2010		269,796		$	6.89
Granted		—			—
Exercised		(5,000	)		5.00
Forfeited		(10,250	)		6.78
Expired		—			—

Outstanding at March 31, 2011		254,546		$	6.93		3.00	$	314

Exercisable at March 31, 2011		254,546		$	6.93		3.00	$	314

The following is a summary of activity for the nine months ended March 31, 2011 related to shares granted under the Company’s long-term incentive plans:


	Shares			Weighted Average Grant Date Fair Value
Restricted shares at June 30, 2010		262,095		$	4.55
Granted		30,950			7.92
Vested		(15,950	)		7.84
Forfeited		—			—

Restricted shares at March 31, 2011		277,095		$	4.73

(13) Earnings Per Share Data

Basic earnings per share is based on the weighted average number of common shares and participating securities outstanding during the period. Diluted earnings per share include the dilutive effect of additional potential common shares issuable under our stock-based compensation plan and are determined using the treasury stock method. Unvested restricted stock awards, which contain non-forfeitable rights to dividends whether paid or unpaid, are included in the number of shares outstanding for both basic and diluted earnings per share calculations. In the event of a net loss, unvested restricted stock awards are excluded from the calculation of both basic and diluted loss per share.

Earnings per share calculations, including weighted average number of shares of common stock outstanding used in calculating basic and diluted net income per share, for the three and nine months ended March 31, 2011 and 2010 are as follows:


	For the Three Months Ended				For the Nine Months Ended
	March 31, 2011		March 31, 2010		March 31, 2011		March 31, 2010
Net income (in thousands)	$	2,523	$	689	$	8,038	$	5,342

Weighted average shares outstanding – Basic		10,223,928		9,978,507		10,211,187		9,964,711
Net effect of dilutive stock options		45,561		19,912		32,774		—

Weighted average shares outstanding – Diluted		10,269,489		9,998,419		10,243,961		9,964,711


Net income per share:
Basic	$	0.25	$	0.07	$	0.79	$	0.54

Diluted	$	0.25	$	0.07	$	0.78	$	0.54

For each of the three and nine months ended March 31, 2011, 277,095 unvested restricted shares were included in determining both basic and diluted earnings per share. For each of the three and nine months ended March 31, 2010, 89,934 unvested restricted shares were included in determining both basic and diluted earnings per share. Potential shares of common stock excluded from diluted income per share computations because their inclusion would be anti-dilutive were 126,551 for both of the three and nine months ended March 31, 2011, respectively, and were 158,546 and 269,796 for the three and nine months ended March 31, 2010.

(14) Comprehensive Income

Comprehensive income, which includes all changes in the Company’s equity during the period except transactions with shareholders, consisted of the following for the three and nine months ended March 31, 2011 and 2010 (in thousands):


	For the Three Months Ended				For the Nine Months Ended
	March 31, 2011		March 31, 2010		March 31, 2011		March 31, 2010
Net income	$	2,523	$	689	$	8,038	$	5,342
Other comprehensive income — Change in unrecognized pension costs, net of tax		140		319		420		956

Comprehensive income	$	2,663	$	1,008	$	8,458	$	6,298

(15) Restructuring Activities

2009 Restructuring Plan

During fiscal 2009, management initiated a full evaluation of the Company’s operations and long-term business strategy. As a result, in the third quarter of fiscal 2009, management began to implement a formal turnaround plan focused on returning Sparton to profitability and the assurance of the Company’s viability (the “2009 Restructuring Plan”). These measures were designed to reduce operating costs, increase efficiencies, and improve our competitive position in response to excess capacity, the prevailing economy and the need to optimize manufacturing resources. These restructuring activities included, among other actions, plant consolidations, closures and sales, workforce reductions, customer contract disengagements, changes in employee pension and health care benefits and relocation of the Company’s corporate office. Restructuring/impairment charges of approximately $11.1 million have been incurred as of March 31, 2011 related to these activities of which approximately $0.0 million, $7.0 million and $0.1 million were related to the Medical, EMS and DSS segments, respectively. The Company does not expect to recognize any additional costs related to these activities. Expected remaining cash expenditures related to the 2009 Restructuring Plan of approximately $0.2 million primarily represent future lease payments and are expected to be paid out by the end of fiscal year 2012.

Delphi Medical Contract Manufacturing Business Acquisition Related Restructuring

During the first quarter of fiscal 2011, the Company took certain cost reduction actions in relation to its acquisition of certain assets related to the contract manufacturing business of Delphi Medical (the “2011 Colorado Restructuring Plan”). These actions included a workforce reduction at the Colorado location and the consolidation of the Colorado manufacturing facilities from two to one. Restructuring/impairment charges recognized within the Medical segment of approximately $0.1 million have been incurred as of March 31, 2011 related to these acquisition related restructuring activities. The Company does not expect to recognize any additional costs related to these activities. All cash expenditures related to the 2011 Colorado Restructuring Plan have been made as of March 31, 2011.

Byers Peak Acquisition Related Restructuring

In conjunction with the Byers Peak acquisition, the Company intends to consolidate the Byers Peak operations into the Company’s Frederick, Colorado facility. These restructuring activities are expected to commence during the Company’s fiscal 2011 fourth quarter.

Summary of Restructuring Charges

The table below summarizes the nature and amount of all restructuring actions for the year ended June 30, 2010 and the nine months ended March 31, 2011 (in thousands):


	Workforce Reduction (principally severance and retention bonuses)			Facility Closing			Lease Termination			Production Transfer		Total
Accrual balance at June 30, 2009	$	375		$	—		$	1,990		$	—	$	2,365
Restructuring charges		350			1,188			409			—		1,947
Less: cash payments		(718	)		(1,175	)		(2,186	)		—		(4,079	)
Restructuring reversals		—			—			—			—		—

Accrual balance at June 30, 2010	$	7		$	13		$	213		$	—	$	233
Restructuring charges		64			13			—			—		77
Less: cash payments		(71	)		(26	)		(61	)		—		(158	)
Restructuring reversals		—			—			—			—		—

Accrual balance at March 31, 2011	$	—		$	—		$	152		$	—	$	152

During the year ended June 30, 2010, approximately $1.4 million of impairment related to property, plant and equipment was recorded. Additionally during fiscal year 2010, the Company sold its Jackson, Michigan and London, Ontario, Canada properties for an aggregate loss of approximately $0.8 million. These impairments and loss on sales related to facility closings were reflected in restructuring/impairment charges for the year ended June 30, 2010.

Given the significance of, and the timing of the execution of such activities, accounting for the expected cost of these actions can involve periodic reassessments of estimates made at the time the original decisions were made. We continually evaluate the adequacy of the remaining liabilities under our restructuring initiatives. Although we believe that these estimates accurately reflect the costs of our restructuring plans, actual results may differ, thereby requiring us to periodically record additional provisions or reverse a portion of such provisions.

(16) Business Segments

Reportable segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or group, in assessing performance and allocating resources. The Company operates predominantly in three markets — Medical Device, Electronic Manufacturing Services and Defense & Security Systems.

The Company uses an internal management reporting system, which provides important financial data to evaluate performance and allocate the Company’s resources on a segment basis. Net sales are attributed to the segment in which the product is manufactured or service is performed. A segment’s performance is evaluated based upon its operating income (loss). A segment’s operating income (loss) includes its gross profit on sales less its selling and administrative expenses, including allocations of certain corporate operating expenses, but excludes some corporate and other unallocated items such as, interest expense, interest income, other income (expense) and income tax expense (benefit). Allocations of certain corporate operating expenses are allocated based on the nature of the service provided. Corporate and other unallocated costs primarily represent corporate administrative expenses related to those administrative, financial and human resource activities which are not allocated to operations and excluded from segment profit. These costs are not allocated to the segments, as management excludes such costs when assessing the performance of the segments. Inter-segment transactions are generally accounted for at amounts that approximate arm’s length transactions. Identifiable assets by segments are those assets that are used in each segment’s operations. The accounting policies for each of the segments are the same as for the Company taken as a whole.

Medical Device (“Medical”) operations are comprised of contract development, design, production and distribution of complex and sophisticated medical related electromechanical devices for customers with specialized needs, specifically in the design and manufacturing process, to assure product reliability and safety in accordance with Food and Drug Administration (“FDA”) guidelines and approvals. This group specializes in systems and procedures targeted to the requirements of medical Original Equipment Manufacturers (“OEM”) and Emerging Technology (“ET”) customers primarily in the In Vitro Diagnostic and Therapeutic Device segments of the Medical Device market space.

Electronic Manufacturing Services (“EMS”) operations are comprised of contract manufacturing, assembly, design, preproduction, prototyping and/or box build assembly for customers supporting the industrial, security sensing, medical, aerospace, defense, energy and telecommunications markets. These assemblies include flight control systems, fuel control systems for aerospace, medical diagnostics systems, security systems, detection systems, lighting and defense. Assemblies provided to this group’s customers are state-of-the-art electronics, complex and legacy products (circuit card assemblies) and/or electromechanical assemblies in support of their products. EMS provides to its customers support services that include engineering services, design, material management, obsolescence analysis and management, documentation development, and process improvement. The segment strives to exceed customer’s expectations of low cost and delivery performance. The common elements generally shared by EMS customers that produce the aforementioned products is the expectation of compliance to market quality certifications coupled with component cost reduction and continuous process improvements.

Defense & Security Systems (“DSS”) operations are comprised of design, development and production of products for a number of technologically significant programs aimed at fulfilling defense and commercial needs. Specializing in the development and production of complex electromechanical equipment, Sparton designs and manufactures sonobuoys, an anti-submarine warfare (“ASW”) device used by the U.S. Navy and foreign governments. This business unit also performs an engineering development function for the United States military and prime defense contractors on advanced technologies targeted as future defense products as well as replacement of current systems. The sonobuoy product line is built to the customer’s demanding specifications. These products are restricted by International Tariff and Arms Regulations (“ITAR”), which limits opportunities for competition.

Operating results and certain other financial information about the Company’s three reportable segments for the three and nine months ended March 31, 2011 and 2010 and as of March 31, 2011 and June 30, 2010 were as follows (in thousands):


	For the Three Months Ended March 31, 2011
	Medical			EMS			DSS		Other Unallocated			Eliminations			Total
Sales	$	25,377		$	12,291		$	16,350	$	—		$	(3,666	)	$	50,352
Gross profit	$	3,554		$	1,364		$	3,284	$	—		$	—		$	8,202
Operating income (loss)	$	2,044		$	568		$	2,068	$	(2,001	)	$	—		$	2,679
Selling and administrative expenses	$	1,383		$	796		$	934	$	2,030		$	—		$	5,143
Gain on sale of property, plant and equipment	$	—		$	—		$	—	$	(121	)	$	—		$	(121	)
Depreciation/amortization	$	191		$	120		$	61	$	17		$	—		$	389
Capital expenditures	$	30		$	178		$	409	$	295		$	—		$	912

	For the Three Months Ended March 31, 2010
	Medical			EMS			DSS		Other Unallocated			Eliminations			Total
Sales	$	14,228		$	13,076		$	14,293	$	—		$	(2,960	)	$	38,637
Gross profit	$	1,474		$	620		$	3,475	$	—		$	—		$	5,569
Operating income (loss)	$	327		$	(426	)	$	2,784	$	(2,307	)	$	—		$	378
Selling and administrative expenses	$	1,029		$	862		$	691	$	1,746		$			$	4,328
Restructuring/impairment charges	$	—		$	184		$	—	$	54		$	—		$	238
Depreciation/amortization	$	159		$	129		$	35	$	5		$	—		$	328
Capital expenditures	$	40		$	179		$	126	$	9		$	—		$	354

	For the Nine Months Ended March 31, 2011
	Medical			EMS			DSS		Other Unallocated			Eliminations			Total
Sales	$	70,072		$	35,131		$	47,126	$	—		$	(9,879	)	$	142,450
Gross profit	$	9,211		$	3,020		$	10,544	$	—		$	—		$	22,775
Operating income (loss)	$	6,691		$	559		$	7,459	$	(6,345	)	$	—		$	8,364
Selling and administrative expenses	$	4,496		$	2,479		$	2,521	$	6,170		$	—		$	15,666
Restructuring/impairment charges	$	77		$	—		$	—	$	—		$	—		$	77
Gain on sale of property, plant and equipment	$	—		$	(18	)	$	—	$	(121	)	$	—		$	(139	)
Gain on acquisition	$	(2,400	)	$	—		$	—	$	—		$	—		$	(2,400	)
Depreciation/amortization	$	531		$	347		$	145	$	53		$	—		$	1,076
Capital expenditures	$	30		$	1,044		$	811	$	389		$	—		$	2,274

	For the Nine Months Ended March 31, 2010
	Medical			EMS			DSS		Other Unallocated			Eliminations			Total
Sales	$	51,142		$	45,003		$	46,660	$	—		$	(8,841	)	$	133,964
Gross profit	$	6,871		$	2,349		$	11,856	$	—		$	—		$	21,076
Operating income (loss)	$	3,733		$	(1,189	)	$	9,861	$	(8,939	)	$	—		$	3,466
Selling and administrative expenses	$	2,786		$	2,545		$	1,995	$	6,691		$			$	14,017
Restructuring/impairment charges	$	—		$	993		$	—	$	1,128		$	—		$	2,121
Depreciation/amortization	$	465		$	473		$	117	$	12		$	—		$	1,067
Capital expenditures	$	144		$	656		$	200	$	41		$	—		$	1,041

	As of March 31, 2011
	Medical			EMS			DSS		Other Unallocated			Eliminations			Total
Total assets	$	70,088		$	24,990		$	5,103	$	30,879		$	—		$	131,060

	As of June 30, 2010
	Medical			EMS			DSS		Other Unallocated			Eliminations			Total
Total assets	$	46,695		$	25,219		$	5,980	$	41,967		$	—		$	119,861

(17) New Accounting Standard

In July 2010, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2010-20, “Disclosures about the Credit Quality of Financing Receivables and the Allowance for Credit Losses”, (“ASU 2010-20”). This update enhances the disclosure requirements about the credit quality and related allowance for credit losses of financing receivables. ASU 2010-20 was effective for Sparton in the second quarter of fiscal 2011. The adoption of this disclosure guidance did not have a significant impact on the Company’s consolidated financial statements.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following is management’s discussion and analysis of certain significant events affecting Sparton Corporation’s (the “Company” or “Sparton”) results of operations and financial condition during the periods included in the accompanying financial statements. Additional information regarding the Company can be accessed via Sparton’s website at www.sparton.com. Information provided at the website includes, among other items, the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Quarterly Earnings Releases, News Releases, and the Code of Business Conduct and Ethics, as well as various corporate charters and documents.

The Private Securities Litigation Reform Act of 1995 reflects Congress’ determination that the disclosure of forward-looking information is desirable for investors and encourages such disclosure by providing a safe harbor for forward-looking statements by corporate management. This report on Form 10-Q contains forward-looking statements within the scope of the Securities Act of 1933 and the Securities Exchange Act of 1934. The words “expects,” “anticipates,” “believes,” “intends,” “plans,” “will,” “shall,” and similar expressions, and the negatives of such expressions, are intended to identify forward-looking statements. In addition, any statements which refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The Company undertakes no obligation to publicly disclose any revisions to these forward-looking statements to reflect events or circumstances occurring subsequent to filing this Form 10-Q with the Securities and Exchange Commission (“SEC”). These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed below and those described in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended June 30, 2010. Accordingly, Sparton’s future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. The Company notes that a variety of factors could cause the actual results and experience to differ materially from anticipated results or other expectations expressed in the Company’s forward-looking statements.

Business Overview

General

Sparton is a provider of complex and sophisticated electromechanical devices with capabilities that include concept development, industrial design, design and manufacturing engineering, production, distribution, and field service. The Company operates predominantly in three markets — Medical Device (“Medical”), Electronic Manufacturing Services (“EMS”) and Defense & Security Systems (“DSS”).

All of the Company’s facilities are registered to ISO standards, including 9001 or 13485, with most having additional certifications. The Company’s products and services include products for Original Equipment Manufacturers (“OEM”) and Emerging Technology (“ET”) customers that are microprocessor-based systems that include transducers, printed circuit boards and assemblies, sensors, and electromechanical components, as well as development and design engineering services relating to these product sales. Sparton also develops and manufactures sonobuoys, an anti-submarine warfare (“ASW”) device, used by the United States Navy and other free-world countries. Many of the physical and technical attributes in the production of sonobuoys are similar to those required in the production of the Company’s other electrical and electromechanical products and assemblies.

The Company uses an internal management reporting system, which provides important financial data to evaluate performance and allocate the Company’s resources on a market segment basis. Net sales for segments are attributed to the segment in which the product is manufactured or service is performed. A segment’s performance is evaluated based upon its operating income (loss). A segment’s operating income (loss) includes its gross profit on sales less its selling and administrative expenses, but excludes some corporate and other unallocated items such as, interest expense, interest income, other income (expense) and income tax expense (benefit). Corporate and other unallocated costs primarily represent corporate administrative expenses related to those administrative, financial and human resource activities which are not allocated to operations and excluded from segment profit. These costs are not allocated to the segments, as management excludes such costs when assessing the performance of the segments. Inter-segment transactions are generally accounted for at amounts that approximate arm’s length transactions. The accounting policies for each of the segments are the same as for the Company taken as a whole.

Medical Segment

Medical operations are comprised of contract development, design, production and distribution of complex and sophisticated medical related electromechanical devices for customers with specialized needs, specifically in the design and manufacturing process, to assure product reliability and safety in accordance with Food and Drug Administration (“FDA”) guidelines and approvals. This group specializes in systems and procedures targeted to the requirements of medical OEM and ET customers primarily in the In Vitro Diagnostic and Therapeutic Device segments of the Medical Device market space.

EMS Segment

EMS operations are comprised of contract manufacturing, assembly, design, preproduction, prototyping and/or box build assembly for customers supporting the industrial, security sensing, medical, aerospace, defense, energy and telecommunications markets. These assemblies include flight control systems, fuel control systems for aerospace, medical diagnostics systems, security systems, detection systems, lighting and defense. Assemblies provided to this group’s customers are state-of-the-art electronics, complex and legacy products (circuit card assemblies) and/or electromechanical assemblies in support of their products. EMS provides to its customers support services that include engineering services, design, material management, obsolescence analysis and management, documentation development, and process improvement. The segment strives to exceed customer’s expectations of low cost and delivery performance. The common elements generally shared by EMS customers that produce the aforementioned products is the expectation of compliance to market quality certifications coupled with component cost reduction and continuous process improvements.

DSS Segment

DSS operations are comprised of design, development and production of products for a number of technologically significant programs aimed at fulfilling defense and commercial needs. Specializing in the development and production of complex electromechanical equipment, Sparton designs and manufactures sonobuoys, an ASW device used by the U.S. Navy and foreign governments. This business unit also performs an engineering development function for the United States military and prime defense contractors on advanced technologies targeted as future defense products as well as replacement of current systems. The sonobuoy product line is built to the customer’s demanding specifications. These products are restricted by International Tariff and Arms Regulations (“ITAR”), which limits opportunities for competition.

Risks and Uncertainties

Sparton, as a high-mix, low to medium volume supplier, provides rapid product turnaround for customers. High-mix describes customers needing multiple product types with generally low to medium volume manufacturing runs. As a contract manufacturer with customers in a variety of markets, the Company has substantially less visibility of end user demand and, therefore, forecasting sales can be problematic. Customers may cancel their orders, change production quantities and/or reschedule production for a number of reasons. Depressed economic conditions may result in customers delaying delivery of product, or the placement of purchase orders for lower volumes than previously anticipated. Unplanned cancellations, reductions, or delays by customers may negatively impact the Company’s results of operations. As many of the Company’s costs and operating expenses are relatively fixed within given ranges of production, a reduction in customer demand can disproportionately affect the Company’s gross margins and operating income. The majority of the Company’s sales have historically come from a limited number of customers. Significant reductions in sales to, or a loss of, one of these customers could materially impact our operating results if the Company were not able to replace those sales with new business.

Other risks and uncertainties that may affect our operations, performance, growth forecasts and business results include, but are not limited to, timing and fluctuations in U.S. and/or world economies, sharp volatility of world financial markets over a short period of time, competition in the overall contract manufacturing business, availability of production labor and management services under terms acceptable to the Company, Congressional budget outlays for sonobuoy development and production, Congressional legislation, uncertainties associated with the outcome of litigation, changes in the interpretation of environmental laws and the uncertainties of environmental remediation and customer labor and work strikes. Further risk factors are the availability and cost of materials, as well as non-cancelable purchase orders we have committed to in relation to customer forecasts that can be subject to change. A number of events can impact these risks and uncertainties, including potential escalating utility and other related costs due to natural disasters, as well as political uncertainties such as the unrest in Africa and the Middle East. The February 2011 earthquake, tsunami and resultant nuclear disaster in Japan has the potential to cause availability and pricing issues relating to certain materials used within the Company’s products. The Company currently does not believe that the effects of these events will have a material impact on its business. Additional trends, risks and uncertainties that have arisen recently include dependence on key personnel, recent volatility in the stock markets, the impact on the Company’s pension plan and risks surrounding the Company’s recent acquisitions. Finally, the Sarbanes-Oxley Act of 2002, and more recently the Dodd-Frank Act have required or will require changes in, and formalization of, some of the Company’s corporate governance and compliance practices. The SEC and the New York Stock Exchange have also passed or will pass related rules and regulations requiring additional compliance activities. Compliance with these rules has increased administrative costs and may increase these costs further in the future. A further discussion of the Company’s risk factors has been included in Part I, Item 1A. Risk Factors, of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2010. Management cautions readers not to place undue reliance on forward-looking statements, which are subject to influence by the enumerated risk factors as well as unanticipated future events.

Acquisition of Delphi Medical

On August 6, 2010, the Company completed the acquisition of certain assets related to the contract manufacturing business of Delphi Medical Systems, LLC (“Delphi Medical” or “Delphi”). The purchase price was approximately $8.6 million, including additional consideration paid during the three months ended December 31, 2010 related to determination of the final inventory value. Total cash consideration paid of approximately $8.4 million, including a $2.0 million escrowed holdback, was net of approximately $0.2 million for the assumption of retained employee accruals and was financed entirely through the use of Company cash. The purchase agreement provides for the recovery from Delphi Medical of an amount up to $2.0 million, deposited in escrow at closing, for certain excess and obsolete inventory remaining on-hand at the end of the 18 month period from closing. These escrowed funds are additionally available for payment of potential seller indemnification obligations in relation to the agreement.

The acquired business, also now referred to as SMS Colorado, which is reported in the Company’s Medical segment, is expected to add $32 million in projected annual revenue from a new and diversified customer base and provides Sparton with a geographic presence in the western United States. Delphi Medical primarily manufactures OEM medical devices including blood separation equipment, spinal surgery products and 3-D eye mapping devices. It also provides engineering and manufacturing support to a market-leading environmental sensor company whose markets include meteorology, weather critical operations and controlled environment applications.

The following table summarizes, on a pro forma basis, the results of operations of the acquired contract manufacturing business of Delphi Medical as though the acquisition had occurred as of July 1, 2009. The pro forma amounts presented are not necessarily indicative of either the actual consolidated results had the acquisition occurred as of July 1, 2009 or of future consolidated operating results (in thousands):


	For the Three Months Ended March 31,					For the Nine Months Ended March 31,
	2011		2010			2011									2010
	Post Acquisition		SMS Colorado Pro Forma			Pre Acquisition			Post Acquisition			SMS Colorado Pro Forma			SMS Colorado Pro Forma
Net sales	$	10,526	$	7,153		$	3,451		$	27,822		$	31,273		$	23,701
Gross profit	$	1,741	$	(29	)	$	85		$	4,063		$	4,148		$	(29	)
Gain on acquisition	$	—	$	—		$	—		$	(2,400	)	$	(2,400	)	$	—
Operating income (loss)	$	1,050	$	(480	)	$	(85	)	$	4,541		$	4,456		$	(1,409	)
Income before provision for (benefit from) income taxes	$	1,126	$	(350	)	$	(77	)	$	4,749		$	4,672		$	(868	)
Net income (loss)	$	1,126	$	(350	)	$	(77	)	$	4,749		$	4,672		$	(868	)

Acquisition of Byers Peak

On March 4, 2011, the Company completed the acquisition of certain assets and assumption of certain liabilities of Byers Peak, Incorporated (“Byers Peak”) in an approximate $4.4 million all-cash transaction, subject to certain post-closing adjustments. The transaction was financed through the use of Company cash and included an approximate $0.4 million holdback which is available to fund potential seller indemnification obligations in relation to the agreement.

The acquired business, also now referred to as BP Colorado, which is reported in the Company’s Medical segment, provides further expansion into the therapeutic device market, diversifies Sparton’s customer base, and further expands the Company’s geographic reach into the western United States. Additionally, the acquisition increases Sparton’s offerings with the inclusion of field service and refurbishment capabilities. Byers Peak primarily manufactures medical devices for OEM and emerging technology companies in the Therapeutic device market, including devices for surgical navigation, RF energy generation, non-invasive pain relief, arterial disease, and kidney dialysis. It also has a field service and installation group that primarily provides water filtration and disinfection systems for the medical industry as well as device refurbishment programs. Additionally, Byers Peak provides electromechanical device manufacturing support for a limited number of customers outside of the medical industry.

The following table summarizes, on a pro forma basis, the results of operations of the acquired contract manufacturing business of Byers Peak as though the acquisition had occurred as of July 1, 2009. The pro forma amounts presented are not necessarily indicative of either the actual consolidated results had the acquisition occurred as of July 1, 2009 or of future consolidated operating results (in thousands):


	For the Three Months Ended March 31,											For the Nine Months Ended March 31,
	2011									2010		2011									2010
	Pre Acquisition			Post Acquisition			BP Colorado Pro Forma			BP Colorado Pro Forma		Pre Acquisition			Post Acquisition			BP Colorado Pro Forma			BP Colorado Pro Forma
Net sales	$	1,802		$	269		$	2,071		$	2,274	$	6,613		$	269		$	6,882		$	5,985
Gross profit	$	245		$	(40	)	$	205		$	477	$	1,063		$	(40	)	$	1,023		$	1,192
Operating income (loss)	$	(60	)	$	(93	)	$	(153	)	$	107	$	(103	)	$	(93	)	$	(196	)	$	70
Income before provision for (benefit from) income taxes	$	(60	)	$	(93	)	$	(153	)	$	107	$	(103	)	$	(93	)	$	(196	)	$	70
Net income (loss)	$	(60	)	$	(93	)	$	(153	)	$	107	$	(103	)	$	(93	)	$	(196	)	$	70

Consolidated Results of Operations

The following discussion should be read in conjunction with the Unaudited Condensed Consolidated Financial Statements and Notes thereto included in Item 1 of this report.

Summary

The major elements affecting net income for the three and nine months ended March 31, 2011 as compared to the three and nine months ended March 31, 2010 were as follows (in millions):


	For the Three Months Ended March 31,					For the Nine Months Ended March 31,
Net income fiscal 2010				$	0.7				$	5.3
Increased gross profit from acquired Medical businesses	$	1.7				$	4.0
Increased (decreased) gross profit on Strongsville Medical programs		0.4					(1.7	)
Increased gross profit on EMS programs		0.7					0.7
Decreased gross profit on DSS programs		(0.2	)				(1.3	)
Increased selling and administrative expenses		(0.8	)				(1.6	)
Increased internal research and development expenses		(0.3	)				(0.6	)
Decreased restructuring/impairment charges		0.2					2.0
Gain on acquisition		—					2.4
Gain on sale of property, plant and equipment		0.1					0.1
Decreased carrying costs for closed facilities		0.4					0.8
Income taxes		(0.2	)				(2.2	)
Other		(0.2	)				0.1

Net change					1.8					2.7

Net income fiscal 2011				$	2.5				$	8.0

Fiscal 2011 was comparatively impacted by:

•

Incremental gross profit on Medical programs acquired from Delphi Medical and Byers Peak.

•

Decreased year-to-date gross profit on Medical programs from the Strongsville, Ohio facility due to decreased capacity utilization, unfavorable product mix and customer pricing adjustments for the nine month period, partially offset by improved comparative performance from this facility during the third quarter.

•

Increased gross profit on EMS programs due mainly to plant closures and consolidations (for the year-to-date comparative period only), favorable product mix and an aggressive continuous improvement program, partially offset by a decrease in sales volume.

•

Decreased gross profit on DSS programs due to decreases in sonobuoy sales to foreign governments and in engineering sales revenue, partially offset by higher U.S. Navy sonobuoy production in the current year quarter and increased digital compass sales.

•

Increased selling and administrative expenses for the quarter reflecting additional expenses related to the Company’s Colorado facilities and increased business development expenses, partially offset by reduced information technology expenses. In addition, selling and administrative expenses for the nine month period were further impacted by charges from an unfavorable arbitration award related to a dispute with a disengaged customer, partially offset by reduced selling and administrative expenses due to the consolidation of EMS facilities during fiscal 2010.

•

Internal research and development expenses of approximately $0.3 million and $0.6 million in the three and nine months ended March 31, 2011, respectively, compared to none in each of the comparable fiscal 2010 periods.

•

Restructuring/impairment charges of $0.0 million and $0.1 million in the three and nine months ended March 31, 2011, respectively, compared to $0.2 million and $2.1 million in the comparable fiscal 2010 periods.

•

Fiscal 2011 gain on sale of the Company’s Bluewater Road property in Albuquerque, New Mexico.

•

Reduced closed facility carrying costs due to sales of properties.

•

Fiscal 2010 income tax benefit related to a change in income tax carryback regulations.

Presented below are more detailed comparative data and discussions regarding our consolidated results of operations for the three and nine months ended March 31, 2011 compared to the three and nine months ended March 31, 2010. Results of operations for any period less than one year are not necessarily indicative of results of operations that may be expected for a full year.

For the Three Months Ended March 31, 2011 compared to the Three Months Ended March 31, 2010

The following table presents selected consolidated statement of operations data for the three months ended March 31, 2011 and 2010 (in thousands):


	2011						2010
	Total			% of Sales			Total			% of Sales
Net sales	$	50,352			100.0	%	$	38,637			100.0	%
Cost of goods sold		42,150			83.7			33,068			85.6

Gross profit		8,202			16.3			5,569			14.4
Selling and administrative expenses		5,143			10.2			4,328			11.2
Internal research and development expenses		282			0.6			—			—
Restructuring/impairment charges		—			—			238			0.6
Other operating expense, net		98			0.2			625			1.6

Operating income		2,679			5.3			378			1.0
Total other income (expense), net		(41	)		(0.1	)		179			0.4

Income before provision for (benefit from) income taxes		2,638			5.2			557			1.4
Provision for (benefit from) income taxes		115			0.2			(132	)		(0.4	)

Net income	$	2,523			5.0	%	$	689			1.8	%

The following table presents net sales for the three months ended March 31, 2011 and 2010 (in thousands):


	2011						2010
SEGMENT	Total			% of Total			Total			% of Total			% Change
Medical	$	25,377			50	%	$	14,228			37	%		78	%
EMS		12,291			24			13,076			34			(6	)
DSS		16,350			33			14,293			37			14
Eliminations		(3,666	)		(7	)		(2,960	)		(8	)		24

Totals	$	50,352			100	%	$	38,637			100	%		30

The following table presents gross profit and gross profit as a percent of net sales for the three months ended March 31, 2011 and 2010 (in thousands):


	2011					2010
SEGMENT	Total		GP%			Total		GP%
Medical	$	3,554		14	%	$	1,474		10	%
EMS		1,364		11			620		5
DSS		3,284		20			3,475		24

Totals	$	8,202		16		$	5,569		14

The following table presents operating income (loss) and operating income (loss) as a percent of net sales for the three months ended March 31, 2011 and 2010 (in thousands):


	2011						2010
SEGMENT	Total			% of Sales			Total			% of Sales
Medical	$	2,044			8	%	$	327			2	%
EMS		568			5			(426	)		(3	)
DSS		2,068			13			2,784			19
Other unallocated		(2,001	)		—			(2,307	)		—

Totals	$	2,679			5		$	378			1

Medical

Medical sales in the three months ended March 31, 2011 included $10.8 million of additional sales from the acquisitions of certain assets related to the contract manufacturing businesses of Delphi Medical and Byers Peak. Excluding these fiscal year 2011 incremental sales, Medical sales increased approximately $0.3 million in the three months ended March 31, 2011 as compared with the same quarter last year. This increase in comparable sales was primarily due to $2.3 million of increased sales to one customer, reflecting increased demand for certain programs. Sales to another customer decreased by $1.2 million, reflecting this customer’s disengagement during fiscal 2011. Several other customers in the aggregate accounted for the remaining sales variance. Medical sales are dependent on a small number of key strategic customers. Siemens Diagnostics contributed 21% and 22% of consolidated company net sales during the three months ended March 31, 2011 and 2010, respectively. Fenwal Blood Technologies, which became a customer with the Delphi acquisition, contributed 13% of consolidated company net sales during the three months ended March 31, 2011. Medical backlog was approximately $40.8 million at March 31, 2011. Commercial orders, in general, may be rescheduled or cancelled without significant penalty, and, as a result, may not be a meaningful measure of future sales. A majority of the March 31, 2011 Medical backlog is currently expected to be realized in the next 12 months.

Gross profit varies from period to period and can be affected by a number of factors, including product mix, production efficiencies, capacity utilization, and costs associated with new program introduction. The gross profit percentage on Medical sales increased to 14% from 10% for the three months ended March 31, 2011 and 2010, respectively. This increase in margin on Medical sales reflects the Company’s continued implementation of Lean Enterprise and its cost management efforts to mitigate decreased capacity utilization at the Company’s Strongsville, Ohio facility earlier in the year. The quarter over quarter increase additionally reflects higher margins achieved at the Company’s Frederick, Colorado facility. Gross profit percentage on sales from the businesses acquired during fiscal 2011 was 16% for the three months ended March 31, 2011.

Selling and administrative expenses relating to the Medical segment were $1.4 million and $1.0 million for the three months ended March 31, 2011 and 2010, respectively. Reflected in the three months ended March 31, 2011 are increased direct and allocated expenses related to the Company’s recent acquisitions of $0.7 million. Decreased selling and administrative expenses from the Ohio facility reflected fiscal 2010 bad debt expense of $0.2 million and a decrease in allocated corporate selling and administrative expenses to the Ohio facility in the current fiscal quarter, partially offset by additional business development efforts in the current fiscal quarter.

EMS

EMS sales for the three months ended March 31, 2011 decreased approximately $0.8 million as compared with the same quarter last year. This decrease primarily reflects reduced sales to two customers, whose combined decrease totaled approximately $1.2 million from the prior year quarter. The decreases in sales to each of these customers reflect the quarter over quarter loss of certain programs with these customers. EMS sales include intercompany sales resulting primarily from the production of circuit boards that are then utilized in DSS product sales. Intercompany sales increased approximately $0.7 million in the comparable three month period. These intercompany sales are eliminated in consolidation. Several other customers in the aggregate accounted for the remaining sales variance. Goodrich contributed 10% and 15% of consolidated company net sales during the three months ended March 31, 2011 and 2010, respectively. EMS backlog was approximately $32.7 million at March 31, 2011. Commercial orders, in general, may be rescheduled or cancelled without significant penalty, and, as a result, may not be a meaningful measure of future sales. A majority of the March 31, 2011 EMS backlog is currently expected to be realized in the next 18 months.

The gross profit percentage on EMS sales increased to 11% for the three months ended March 31, 2011 compared to 5% for the three months ended March 31, 2010. The quarter over quarter comparison reflects favorable product mix, improved performance and an aggressive continuous improvement program, partially offset by the impact of the overall decrease in sales volume.

Selling and administrative expenses relating to the EMS segment were $0.8 million for the three months ended March 31, 2011 compared to $0.9 million for the three months ended March 31, 2010, reflecting a decrease in allocated corporate selling and administrative expenses, partially offset by increased business development and safety efforts in the current fiscal quarter.

Restructuring/impairment charges relating to the EMS segment were $0.2 million for the three months ended March 31, 2010. No restructuring/impairment charges relating to the EMS segment were recognized in the current year quarter. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

DSS

DSS sales for the three months ended March 31, 2011 increased by $2.1 million from the third quarter of last fiscal year, reflecting higher U.S. Navy sonobuoy production and, to a lesser extent, increased digital compass sales in the current year quarter. Partially offsetting these increases were decreases in sonobuoy sales to foreign governments and in engineering sales revenue. Total sales to the U.S. Navy in the three months ended March 31, 2011 and 2010 were approximately $15.5 million and $11.9 million, respectively, or 31% of consolidated Company net sales for each of those periods. Sonobuoy sales to foreign governments were $0.1 million and $2.0 million in the three months ended March 31, 2011 and 2010, respectively. DSS backlog was approximately $48.9 million at March 31, 2011. A majority of the March 31, 2011 DSS backlog is currently expected to be realized within the next 12 to 16 months.

The gross profit percentage on DSS sales for the three months ended March 31, 2011 was 20% compared to 24% for the three months ended March 31, 2010. Gross profit percentage was adversely affected in the current year quarter by decreased sales to foreign governments as compared to the prior year quarter, partially offset by favorable product mix on increased U.S. Navy sonobuoy sales.

Selling and administrative expenses relating to the DSS segment were $0.9 million for the three months ended March 31, 2011 compared to $0.7 million for the three months ended March 31, 2010, reflecting increased direct selling and administrative expenses due to increased business development efforts in the current fiscal quarter, partially offset by a decrease in allocated corporate selling and administrative expenses.

Internal research and development expenses reflect costs incurred for the internal development of technologies for use in navigation, oil and gas exploration and port security. These costs include salaries and related expenses, contract labor and consulting costs, materials and the cost of certain research and development specific equipment. The Company incurred $0.3 million of internally funded research and development expenses in the three months ended March 31, 2011. No internally funded research and development expense was incurred in the prior year period.

Other Unallocated

Total corporate selling and administrative expenses were $3.6 million and $3.3 million for the three months ended March 31, 2011 and 2010, respectively, reflecting increased business development expenses and fiscal 2011 legal, professional and travel expenses relating to acquisitions, partially offset by decreased information technology expenses. Of these costs, $1.5 million and $1.6 million, respectively, were allocated to segment operations in these periods. Allocations of corporate selling and administrative expenses are based on the nature of the service provided and can fluctuate from period to period.

Other operating expenses were $0.1 million and $0.5 million for the three months ended March 31, 2011 and 2010, respectively. These expenses primarily represent ongoing costs related to closed facilities and facilities held for sale. The Company sold its last remaining idled facility in February 2011.

No non-segment restructuring/impairment charges were recognized during the three months ended March 31, 2011 and 2010, respectively. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

The Company is responsible for income taxes within each jurisdiction in which it operates. The Company recorded income tax expense of approximately $0.1 million for the three months ended March 31, 2011 compared to an income tax benefit of approximately $0.1 million for the three months ended March 31, 2010. The fiscal 2010 benefit reflects the release of $0.2 million of deferred tax asset valuation allowance in relation to tax regulation changes related to carryback provisions. See Note 9 to the Unaudited Condensed Consolidated Financial Statements for a further discussion of income taxes.

Due to the factors described above, the Company reported net income of $2.5 million ($0.25 per share, basic and diluted) for the three months ended March 31, 2011, compared to net income of $0.7 million ($0.07 per share, basic and diluted) for the corresponding quarter last year.

For the Nine Months Ended March 31, 2011 compared to the Nine Months Ended March 31, 2010

The following table presents selected consolidated statement of operations data for the nine months ended March 31, 2011 and 2010 (in thousands):


	2011						2010
	Total			% of Sales			Total			% of Sales
Net sales	$	142,450			100.0	%	$	133,964			100.0	%
Cost of goods sold		119,675			84.0			112,888			84.3

Gross profit		22,775			16.0			21,076			15.7
Selling and administrative expenses		15,666			11.0			14,017			10.4
Internal research and development expenses		564			0.4			—			—
Restructuring/impairment charges		77			—			2,121			1.6
Gain on acquisition		(2,400	)		(1.7	)		—			—
Other operating expense, net		504			0.4			1,472			1.1

Operating income		8,364			5.9			3,466			2.6
Total other expense, net		(111	)		(0.1	)		(151	)		(0.1	)

Income before provision for income taxes		8,253			5.8			3,315			2.5
Provision for (benefit from) income taxes		215			0.2			(2,027	)		(1.5	)

Net income	$	8,038			5.6	%	$	5,342			4.0	%

The following table presents net sales for the nine months ended March 31, 2011 and 2010 (in thousands):


	2011						2010
SEGMENT	Total			% of Total			Total			% of Total			% Change
Medical	$	70,072			49	%	$	51,142			38	%		37	%
EMS		35,131			25			45,003			34			(22	)
DSS		47,126			33			46,660			35			1
Eliminations		(9,879	)		(7	)		(8,841	)		(7	)		12

Totals	$	142,450			100	%	$	133,964			100	%		6

The following table presents gross profit and gross profit as a percent of net sales for the nine months ended March 31, 2011 and 2010 (in thousands):


	2011					2010
SEGMENT	Total		GP%			Total		GP%
Medical	$	9,211		13	%	$	6,871		13	%
EMS		3,020		9			2,349		5
DSS		10,544		22			11,856		25

Totals	$	22,775		16		$	21,076		16

The following table presents operating income (loss) and operating income (loss) as a percent of net sales for the nine months ended March 31, 2011 and 2010 (in thousands):


	2011						2010
SEGMENT	Total			% of Sales			Total			% of Sales
Medical	$	6,691			10	%	$	3,733			7	%
EMS		559			2			(1,189	)		(3	)
DSS		7,459			16			9,861			21
Other unallocated		(6,345	)		—			(8,939	)		—

Totals	$	8,364			6		$	3,466			3

Medical

Medical sales in the nine months ended March 31, 2011 included $28.1 million of additional sales from the acquisitions of certain assets related to the contract manufacturing businesses of Delphi Medical and Byers Peak. Excluding these fiscal year 2011 incremental sales, Medical sales decreased approximately $9.2 million in the nine months ended March 31, 2011 as compared with the same period last year. This decrease in comparable sales was primarily due to decreased sales to three customers. Sales to one customer decreased by $4.8 million, reflecting the suspension of production to make product enhancement modifications. This customer has notified the Company that the product enhancement modifications have been made, however, the Company cannot predict at what level sales for this product will resume. Sales to another customer decreased by $2.0 million, reflecting the customer’s inventory reduction efforts in the first six months of fiscal 2011, the end of life of one of its programs and technical issues on another. Sales to a third customer decreased by $2.4 million, reflecting this customer’s disengagement during fiscal 2011. Several other customers in the aggregate accounted for the remaining sales variance. Medical sales are dependent on a small number of key strategic customers. Siemens Diagnostics contributed 19% and 21% of consolidated company net sales during the nine months ended March 31, 2011 and 2010, respectively. Fenwal Blood Technologies, which became a customer with the Delphi acquisition, contributed 12% of consolidated company net sales during the nine months ended March 31, 2011.

The gross profit percentage on Medical sales remained consistent at 13% for each of the nine months ended March 31, 2011 and 2010, respectively. These comparable margins on Medical sales reflect decreased capacity utilization at the Company’s Strongsville, Ohio facility, certain unfavorable product mix between the two periods and the loss of certain favorable materials pricing benefits in the prior year to customer pricing adjustments. These downward pressures on gross margin were partially offset by greater operating efficiencies from consolidation of manufacturing operations and the Company’s continued implementation of Lean Enterprise and its cost management efforts. Gross profit percentage on sales from the businesses acquired during fiscal 2011 was 14% for the period since acquisition.

Selling and administrative expenses relating to the Medical segment were $4.5 million and $2.8 million for the nine months ended March 31, 2011 and 2010, respectively. Reflected in the nine months ended March 31, 2011 are increased direct and allocated expenses related to the Company’s recent acquisitions of $1.9 million. Decreased selling and administrative expenses from the Ohio facility reflect lower bad debt expense and a decrease in allocated corporate selling and administrative expenses to the Ohio facility in the current fiscal period, partially offset by increased business development efforts in the current fiscal period and $0.4 million in charges related to an unfavorable arbitration award related to a dispute with a disengaged customer.

Restructuring/impairment charges relating to the Medical segment were $0.1 million for the nine months ended March 31, 2011 and related to the workforce reduction and facility consolidation at the Company’s Frederick, Colorado facility. No restructuring/impairment charges relating to the Medical segment were recognized in the prior year period. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

On August 6, 2010, the Company completed the acquisition of certain assets related to the contract manufacturing business of Delphi Medical. The Company determined that the fair value of the assets acquired and liabilities assumed related to this acquisition exceeded the total purchase consideration and as a result the Company recorded a gain on acquisition of $2.4 million in nine months ended March 31, 2011. For a further discussion of this acquisition, see Note 2 to the Unaudited Condensed Consolidated Financial Statements.

EMS

EMS sales for the nine months ended March 31, 2011 decreased approximately $9.9 million as compared with the same period last year. This decrease primarily reflects decreased sales to three customers, whose combined decrease totaled approximately $11.7 million from the prior year period. Sparton completed its disengagement with one of these customers, Honeywell, during the three months ended December 31, 2010. The decreases in sales to the remaining two customers reflect the period over period loss of certain programs with these customers and production delays due to customer engineering design changes. Partially offsetting these decreases, sales to another customer increased by approximately $0.9 million. EMS sales include intercompany sales resulting primarily from the production of circuit boards that are then utilized in DSS product sales. Intercompany sales increased approximately $1.0 million in the comparable nine month period. These intercompany sales are eliminated in consolidation. Several other customers in the aggregate accounted for the remaining sales variance. One customer, Goodrich, contributed 10% and 13% of consolidated Company net sales during the nine months ended March 31, 2011 and 2010, respectively.

The gross profit percentage on EMS sales increased to 9% for the nine months ended March 31, 2011 compared to 5% for the nine months ended March 31, 2010. The period over period comparison reflects improved performance, consolidation of EMS operations, favorable product mix and an aggressive continuous improvement program, partially offset by the overall decrease in sales volume. Additionally offsetting these improvements, margin was favorably impacted in the prior year period by elevated margins on sales to Honeywell during its disengagement. Plant closures and restructuring activities are discussed further in Note 15 of the Unaudited Condensed Consolidated Financial Statements.

Selling and administrative expenses relating to the EMS segment were $2.5 million for each of the nine months ended March 31, 2011 and 2010, respectively, as decreased expenses related to the consolidation of EMS facilities during fiscal 2010 and decreased allocated corporate selling and administrative expenses were offset by increased business development and safety efforts in the current fiscal year.

Restructuring/impairment charges relating to the EMS segment were $1.0 million for the nine months ended March 31, 2010. No restructuring/impairment charges relating to the EMS segment were recognized in the current year period. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

DSS

DSS sales for the nine months ended March 31, 2011 increased by $0.5 million from the first nine months of last fiscal year, reflecting higher U.S. Navy sonobuoy production in the current year period and increased digital compass sales. Partially offsetting these increases were decreases in sonobuoy sales to foreign governments and in engineering sales revenue. Total sales to the U.S. Navy in the nine months ended March 31, 2011 and 2010 were approximately $41.1 million and $34.4 million, or 29% and 26%, respectively, of consolidated Company net sales for those periods. Sonobuoy sales to foreign governments were $3.7 million and $10.8 million in the nine months ended March 31, 2011 and 2010, respectively.

The gross profit percentage on DSS sales for the nine months ended March 31, 2011 was 22% compared to 25% for the nine months ended March 31, 2010. Gross profit percentage was adversely affected in the current year period by decreased sales to foreign governments as compared to the prior year period, partially offset by favorable product mix on increased U.S. Navy sonobuoy sales.

Selling and administrative expenses relating to the DSS segment were $2.5 million and $2.0 million for the nine months ended March 31, 2011 and 2010, respectively, reflecting increased direct selling and administrative expenses due to increased business development efforts in the current fiscal period.

Internal research and development expenses reflect costs incurred for the internal development of technologies for use in navigation, oil and gas exploration and port security. These costs include salaries and related expenses, contract labor and consulting costs, materials and the cost of certain research and development specific equipment. The Company incurred $0.6 million of internally funded research and development expenses in the nine months ended March 31, 2011. No internally funded research and development expense was recognized in the prior year period.

Other Unallocated

Total corporate selling and administrative expenses were $11.1 million and $11.2 million for the nine months ended March 31, 2011 and 2010, respectively, reflecting, decreased information technology expenses, partially offset by increased business development expenses and fiscal 2011 legal, professional and travel expenses relating to acquisitions. Of these costs, $4.9 million and $4.5 million, respectively, were allocated to segment operations in these periods. Allocations of corporate selling and administrative expenses are based on the nature of the service provided and can fluctuate from period to period.

Other operating expenses were $0.3 million and $1.1 million for the nine months ended March 31, 2011 and 2010, respectively. These expenses primarily represent ongoing costs related to closed facilities and facilities held for sale. The Company sold its last remaining idled facility in February 2011.

Non-segment related restructuring/impairment charges were $1.1 million for the nine months ended March 31, 2010 and were related to relocation of the Company’s corporate office. No non-segment restructuring/impairment charges were recognized in the current year nine month period. For a further discussion of the restructuring activity see Note 15 to the Unaudited Condensed Consolidated Financial Statements.

Interest expense consists of interest and fees on our outstanding debt and revolving credit facility (see Note 7 to the Unaudited Condensed Consolidated Financial Statements), including amortization of financing costs. Interest expense was $0.5 million for the nine months ended March 31, 2011 compared to $0.7 million for the nine months ended March 31, 2010. The decrease primarily reflects the repayment of the Company’s line-of-credit and bank term debt with available cash on August 14, 2009.

The Company is responsible for income taxes within each jurisdiction in which it operates. The Company recorded income tax expense of approximately $0.2 million for the nine months ended March 31, 2011 compared to an income tax benefit of approximately $2.0 million for the nine months ended March 31, 2010. The fiscal 2011 income tax expense includes a $0.1 million benefit relating to income tax carryback refunds received from the Canadian government. The fiscal 2010 benefit reflects the release of $2.3 million of deferred tax asset valuation allowance in relation to tax regulation changes related to carryback provisions. See Note 9 to the Unaudited Condensed Consolidated Financial Statements for a further discussion of income taxes.

Due to the factors described above, the Company reported net income of $8.0 million ($0.79 per basic share and $0.78 per diluted share) for the nine months ended March 31, 2011, compared to net income of $5.3 million ($0.54 per share, basic and diluted) for the corresponding period last year.

Liquidity and Capital Resources

Certain of the Company’s DSS contracts allow for billings to occur when certain milestones under the applicable program are reached, independent of the amount shipped by Sparton as of such date. These advance billings reduce the amount of cash that would otherwise be required during the performance of these contracts. As of March 31, 2011 and June 30, 2010, $19.3 million and $21.6 million, respectively, of billings in excess of costs were received. The Company currently expects to meet its liquidity needs through a combination of sources including, but not limited to, operations, existing cash balances, its revolving line-of-credit, anticipated continuation of advance billings on certain DSS contracts and improvement in inventory management. With the above sources providing the expected cash flows, the Company currently believes that it will have sufficient liquidity for our anticipated needs over the next 12 months, but no assurances regarding liquidity can be made.

Operating activities provided $3.4 million and $5.0 million of net cash flows in the nine months ended March 31, 2011 and 2010, respectively. Excluding changes in working capital, operating activities provided $8.1 million and $8.5 million in the first nine months of fiscal 2011 and 2010, respectively, reflecting the Company’s relative operating performance during those periods. Working capital used $4.7 million and $3.5 million of net cash flows in the nine months ended March 31, 2011 and 2010, respectively. Working capital related cash flows in the first nine months of fiscal 2011 primarily reflect funding of production related to U.S. Navy contracts during the nine month period in excess of advance billings received, the initial working capital funding related the Company’s newly acquired Frederick, Colorado facility as well as a funding of a pension contribution during the period. Working capital related cash flows in the first nine months of fiscal 2010 primarily reflect the funding of production related to U.S. Navy contracts during the year in excess of advance billings received as well as cash outlays relating to restructuring activities and a pension contribution, offset by reduced working capital requirements related to lower sales volumes due to customer disengagements, the closing of facilities and the Company’s inventory management efforts.

Cash flows used in investing activities in the nine months ended March 31, 2011 and 2010 totaled $7.8 million and $4.2 million, respectively. The nine months ended March 31, 2011 reflect the acquisition of certain assets related to the contract manufacturing business of Delphi Medical. The consideration paid of $8.4 million is net of assumed employee accrual adjustments. Fiscal 2011 also reflects the $4.35 million net acquisition of certain assets and assumption of certain liabilities of Byers Peak. These two purchases were financed entirely through the use of Company cash. The nine months ended March 31, 2010 reflects the payment of contingent purchase consideration to the prior owners of Astro Instrumentation, LLC. Fiscal 2010 also reflects the utilization of $3.1 million to establish a trust, the Sparton Corporation Financial Assurance Trust, related to environmental remediation activities at one of Sparton’s former facilities. The funds were held in Sparton’s name and were invested with Sparton receiving the benefit of the investment return. Investment returns on the funds during the nine months ended March 31, 2010 totaled approximately $0.1 million. These funds were available for use to satisfy the expected remediation liability reflected in the June 30, 2010 balance sheet. Fiscal 2011 reflects the Company’s dissolution of the trust during October 2010. For further discussion of this remediation activity, see “Commitments and Contingencies” below. Capital expenditures for the nine months ended March 31, 2011 and 2010 were approximately $2.3 million and $1.0 million, respectively. Proceeds from the sale of property, plant and equipment for the nine months ended March 31, 2011 and 2010 were approximately $4.0 million and $0.5 million, respectively. Fiscal 2011 proceeds from the sale of property, plant and equipment primarily represent the February 2011 sale of the Company’s Bluewater Road property in Albuquerque, New Mexico. Fiscal 2010 proceeds from the sale of property, plant and equipment represent equipment sales related to the closure of the Company’s Jackson, Michigan facility. In addition, fiscal 2010 reflects proceeds from the sale of a portion of the Company’s interest in Cybernet totaling approximately $0.5 million.

Cash flows used in financing activities in the nine months ended March 31, 2011 and 2010 totaled approximately $0.1 million and $20.9 million, respectively. The primary use of cash from financing activities in the first nine months of fiscal 2010 was the repayment of debt. Fiscal 2010 also reflects the payment of financing fees related to the Company’s revolving credit facility. In the nine months ended March 31, 2010, the Company paid off the existing balance on its line-of-credit facility totaling $15.5 million and the $3.4 million remaining balance on its term loan with National City Bank.

As of March 31, 2011, the Company’s bank line-of-credit facility totaled $20.0 million, subject to certain collateral restrictions, with no borrowings against the available funds. The Company did have certain letters of credit outstanding against this facility totaling $0.5 million at March 31, 2011. This bank debt is subject to certain customary covenants which were met at March 31, 2011. The maturity date for this line-of-credit is August 14, 2012. The Company also has approximately $1.8 million of industrial revenue bonds outstanding at March 31, 2011. See Note 7, Debt, of the “Notes to Condensed Consolidated Financial Statements” in this Quarterly Report on Form 10-Q for a further discussion of the Company’s debt.

Commitments and Contingencies

Environmental Remediation

Sparton has been involved with ongoing environmental remediation since the early 1980’s related to one of its former manufacturing facilities, located in Albuquerque, New Mexico (“Coors Road”). Although the Company entered into a long-term lease of the Coors Road property that was treated as a sale of property during the fourth quarter of fiscal 2010, it remains responsible for the remediation obligations related to its past operation of this facility. At March 31, 2011, Sparton had accrued approximately $4.3 million as its estimate of the remaining minimum future undiscounted financial liability with respect to this matter, of which approximately $0.5 million is classified as a current liability and included on the balance sheet in other accrued expenses. The Company’s minimum cost estimate is based upon existing technology and excludes certain legal costs, which are expensed as incurred. The Company’s estimate includes equipment and operating and maintenance costs for onsite and offsite pump and treat containment systems, as well as continued onsite and offsite monitoring. It also includes periodic reporting requirements.

Customer Relationships

The Company had an action before the U.S. Court of Federal Claims to recover damages arising out of an alleged infringement by the U.S. Navy of certain patents held by Sparton and used in the production of sonobuoys. Pursuant to an agreement between the Company and counsel conducting the litigation, a significant portion of the claim will be retained by the Company’s counsel in contingent fees if the litigation is successfully concluded. A trial of the matter was conducted by the court in April 2008, with a decision against Sparton filed in August 2009 and published in September 2009. In October 2009, an appeal of this unfavorable decision was filed with the Federal Circuit Court of Appeals. Based on this decision, management believes that the Company’s ability to obtain any recovery with respect to the claim is remote.

Litigation

On August 9, 2009, Sparton and certain subsidiaries were named as defendants in a wrongful death suit, alleging that a defective transmission shifter assembly in a 1996 Chrysler automobile caused a July 2007 death. The suit also named Chrysler LLC, Dura Automotive Systems, Inc., and Chandler Motors Company as defendants. The suit was filed in Pontotoc County Circuit Court in Mississippi. Sparton has not manufactured automotive shifter assemblies for Chrysler since December 1996, when it sold its KPI Group subsidiary to Dura Automotive Systems, Inc. The plaintiff seeks damages from the defendants for economic loss, pain and suffering, and loss of companionship, as well as punitive damages. Sparton has denied liability, has notified its insurance carriers regarding this claim, and is vigorously defending this matter. At this time, it is not possible to determine or predict the outcome of this suit, and as a result, no amounts have been accrued in the financial statements as of March 31, 2011. While no assurances can be given, the Company does not believe that this litigation, if adversely determined, would have a material adverse affect on the Company’s financial position or results of operations.

Other

In addition to the foregoing, from time to time, the Company is involved in various legal proceedings relating to claims arising in the ordinary course of business. The Company is not currently a party to any other such legal proceedings, the adverse outcome to which, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition or results of operations.

Contractual Obligations and Off-Balance Sheet Arrangements

Information regarding the Company’s long-term debt obligations, environmental liability payments, operating lease payments, and other commitments is provided in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2010. As discussed in Note 2 to the Unaudited Condensed Consolidated Financial Statements in this Quarterly Report, concurrent with the August 2010 acquisition of certain assets of the contract manufacturing business of Delphi Medical, the Company entered into a lease of the facility housing the operations of this contract manufacturing business. Additionally, as described within this same footnote, concurrent with the March 2011 acquisition of certain assets and assumption of certain liabilities of Byers Peak, the Company entered into a lease of the facility housing the operations of this contract manufacturing business. Due primarily to the leases of these new facilities, contractual obligations under operating leases are now $588,000, $1,850,000, $1,098,000, $714,000, $718,000 and $1,556,000 for fiscal years 2011, 2012, 2013, 2014, 2015 and thereafter, respectively. In addition, as of June 30, 2010, there were $16.6 million of non-cancelable purchase orders outstanding. This amount has increased to $28.0 million as of March 31, 2011. Other than as noted above, there have been no material changes in the nature or amount of the Company’s contractual obligations since June 30, 2010.

Critical Accounting Policies

Our financial statements are prepared in conformity with GAAP and require us to select appropriate accounting policies. The assumptions and judgments we use in applying our accounting policies have a significant impact on our reported amounts of assets, liabilities, revenue and expenses. While we believe that the assumptions and judgments used in our estimates are reasonable, actual results may differ from these estimates under different assumptions or conditions.

We have identified the most critical accounting policies upon which our financial status depends. The critical policies were determined by considering accounting policies that involve the most complex or subjective decisions or assessments. We also have other policies considered key accounting policies; however, these policies do not meet the definition of critical accounting policies because they do not generally require us to make estimates or judgments that are complex or subjective. Our critical accounting policies include the following:

•

Environmental contingencies

•

Government contract cost estimates

•

Commercial inventory valuation allowances

•

Allowances for probable losses on receivables

•

Pension obligations

•

Business combinations

•

Valuation of property, plant and equipment

•

Goodwill and customer relations

•

Income taxes

•

Restructuring accrual

•

Stock-based compensation

There have been no significant changes to our critical accounting policies that are described in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended June 30, 2010.

New Accounting Pronouncements

See Note 17, Summary of Significant Accounting Policies, of the “Notes to Unaudited Condensed Consolidated Financial Statements” in this Quarterly Report on Form 10-Q for a discussion of new accounting pronouncements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The Company manufactures its products in the United States and Vietnam. Sales are to the U.S. as well as foreign markets. The Company is potentially subject to foreign currency exchange rate risk relating to intercompany activity and balances and to receipts from customers and payments to suppliers in foreign currencies. Also, adjustments related to the translation of the Company’s Vietnamese financial statements into U.S. dollars are included in current earnings. As a result, the Company’s financial results could be affected by factors such as changes in foreign currency exchange rates or economic conditions in the domestic and foreign markets in which the Company operates. However, minimal third party receivables and payables are denominated in foreign currency and the related market risk exposure is considered to be immaterial.

The Company’s revolving credit line, if drawn upon, is subject to future interest rate fluctuations which could potentially have a negative impact on cash flows of the Company. The Company is not party to any currency exchange or interest rate protection agreements as of March 31, 2011.

Item 4. Controls and Procedures.

Each of our Chief Executive Officer and Chief Financial Officer has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934) as of the end of the period covered by this quarterly report. Based on such evaluation, such officers have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures are effective.

There have been no changes in our internal controls over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2011 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Commitments and Contingencies” of this report.

In addition to the above, from time to time, we are involved in various legal proceedings relating to claims arising in the ordinary course of business. We are not currently a party to any such legal proceedings, the outcome of which, individually or in the aggregate, is expected to have a material adverse effect on our business, financial condition or results of operations.

Item 1A. Risk Factors.

You should carefully consider the risks and uncertainties described in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended June 30, 2010 as well as other information in our subsequent filings with the SEC, including this Quarterly Report on Form 10-Q. Our business, financial condition, results of operations and stock price could be materially adversely affected by any of these risks. The risks described in our Annual Report on Form 10-K and our subsequent filings are not the only ones we face. Additional risks and uncertainties that are currently unknown to us or that we currently consider to be immaterial may also impair our business or adversely affect our financial condition, results of operations and stock price.

Item 6. Exhibits.


Exhibit Number		Description

3.1		Second Amended Articles of Incorporation of the Registrant, incorporated herein by reference from the Registrant’s Proxy Statement on Form DEF 14A filed with the SEC on September 21, 2010.

3.2		Amended and Restated Code of Regulations of the Registrant, incorporated herein by reference from the Registrant’s Proxy Statement on Form DEF 14A filed with the SEC on September 21, 2010.

10.1		Amended and Restated Revolving Credit and Security Agreement dated August 14, 2009 among the Company, its subsidiaries and National City Business Credit, Inc., incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 18, 2009.

10.2		Post-closing Agreement dated August 14, 2009 among the Company, its subsidiaries and National City Business Credit, Inc., incorporated by reference from Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 18, 2009.

10.3		Long-Term Stock Option Incentive Plan, incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 11, 2009.

10.4		Lease Extension and Amendment Agreement dated May 1, 2010 between Sparton Technology, Inc. and 9621 Coors, L.L.C., guaranteed by Albuquerque Motor Company, Inc., incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 6, 2010.

10.5		Option Agreement dated May 1, 2010 by and between Sparton Technology, Inc. and 9621 Coors, L.L.C., guaranteed by Albuquerque Motor Company, Inc., incorporated by reference from Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on May 6, 2010.

10.6		Asset Purchase Agreement dated July 9, 2010 between Delphi Medical Systems, LLC and Sparton Medical Systems Colorado, LLC, incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 12, 2010.

10.7		Asset Purchase Agreement dated December 8, 2010 between Coven Holdings LLC and Sparton Technology, Inc., incorporated by reference from Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on December 14, 2010.

31.1*		Chief Executive Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Chief Financial Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*		Chief Executive Officer and Chief Financial Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Sparton Corporation

Date: May 10, 2011	By:	/s/ CARY B. WOOD
		Cary B. Wood
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: May 10, 2011	By:	/s/ GREGORY A. SLOME
		Gregory A. Slome
		Senior Vice President and Chief Financial Officer
		(Principal Financial Officer)

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company